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ABSTRACT OF DISSERTATION 
 
ACTINOMYCIN FAMILIAL DIVERSITY DRIVEN BY PHENOXAZINONE-CORE 
REACTIVITY 
 
Actinomycins are a class of compounds consisting of phenoxazinone-like core 
attached to two peptidolactone rings, denoted as α and β. A unique component of a few 
families—actinomycins G, Y, and Z—is a chlorinated β-ring threonine residue. Families 
G and Y also contained an actinomycin that possess a β-ring heterocycle (actinomycins G5 
and Y5, respectively); prior to this work, no β-ring heterocycle-containing actinomycins 
were reported for the Z family. Unlike other actinomycin derivatives, Y5’s cytotoxicity was 
abolished while still maintaining some antibacterial potency.  
We constructed a model compound to probe the physical properties of the 
actinomycin core to test conditions under which heterocycle formation would occur. We 
also analyzed the gene clusters of these actinomycin producers for gene candidates to from 
this structural motif.  We found the actinomycin core aniline to have pKa values of 2.976 
and 8.429 and a significant shift in UV absorption between 300-310 nm when the group 
becomes charged. We also found cyclization conditions and no obvious gene candidates to 
form the β-ring heterocycle based on our gene cluster analysis. We hypothesize that the 
familial diversity of the actinomycin G, Y and Z families is due to the reactivity of the 
phenoxazinone-like core.  
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Chapter 1: Introduction and Background 
1.1 Actinomycin Discovery 
The first actinomycin molecule to be discovered was actinomycin D in 1940 from 
Streptomyces antibioticus.1 The organism was grown on agar media for 6-8 days, extracted 
with ether, and then redissolved in 95% ethanol. The organic mixture was observed to be 
a bright red color though maintained a yellow color even in concentrations as low as 1 
µg/ml. Initial activity assays of actinomycin D showed it to be a quick and potent cytotoxic 
agent while being slowly bactericidal against both Gram positive and Gram negative. Since 
then, more than 30 naturally occurring actinomycin molecules belonging to approximately 
nine different families have been discovered.2 The family an actinomycin molecule belongs 
to is denoted by the letter following “actinomycin.” Actinomycins with identical α- and β-
rings are denoted as iso-actinomycin; those with differing α- and β-rings are known as 
aniso-actinomycin.3,4 Figure 1.1.1 and Table 1.1.1 highlight many of the known structural 
differences between several families of iso- and aniso-actinomycins.  
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Figure 1.1.1-Actinomycin General Structure 
 
 
 
Structure of actinomycin D. Each amino acid member of the depsipeptide ring is 
highlighted and the phenoxazinone-like core is shown in black to denote the different areas 
of the actinomycin scaffold. Within the core, the aniline bound to position 2 will be denoted 
as “2-NH2” henceforth.  
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Table 1.1.1-Select Modifications to Actinomycin General Structure 
 
 
The structural components of each actinomycin used whose bioactivity is listed in Table 
1.3.1 
 
rThr: β-ring threonine rearranged to produce unique β-ring core structure 
cO: Oxygen is the heteroatom between 1b and 2-NH2 involved in a β-ring heterocycle  
cNH:  Amine group is the heteroatom between 1b and 2-NH2 involved in a β-ring 
heterocycle  
Neo Act A: Contains a methyl oxazole ring formed at core positions 2 and 3 
Neo Act B: Contains a carboxyethyl oxazole ring formed at core positions 2 and 3 
 
 
 
 
 
 
Cmpd 1α 2α 3α 4α 5α 1β 2β 3β 4β 5β
D Thr D-Val Pro Gly Val Thr D-Val Pro Gly Val
X0β Thr D-Val Pro Gly Val Thr D-Val 4-OH-Pro Gly Val
F8 Thr D-Val Gly Gly Val Thr D-Val Gly Gly Val
F9 Thr D-Val Gly Gly Val Thr D-Val Pro Gly Val
X2 Thr D-Val Pro Gly Val Thr D-Val 4-Oxo-Pro Gly Val
C2 Thr D-Val Pro Gly Val Thr D-Ile Pro Gly Val
C3 Thr D-Ile Pro Gly Val Thr D-Ile Pro Gly Val
Y1 Thr D-Val 3-OH-5-Me-Pro Gly Val 4-Cl-Thr D-Val 4-Oxo-Pro Gly Ala
Y2 Thr D-Val 3-OH-5-Me-Pro Gly Val 4-Cl-Thr D-Val 4-OH-Pro Gly Ala
Y3 Thr D-Val 3-OH-5-Me-Pro Gly Val rThr D-Val 4-Oxo-Pro Gly Ala
Y4 Thr D-Val 3-OH-5-Me-Pro Gly Val rThr D-Val 4-OH-Pro Gly Ala
Y5 Thr D-Val 3-OH-5-Me-Pro Gly Val cNHThr D-Val 4-Oxo-Pro Gly Ala
G2 Thr D-Val 3-OH-5-Me-Pro Gly Val 4-Cl-Thr D-Val Pro Gly Ala
G3 Thr D-Val 3-OH-5-Me-Pro Gly Val 4-OH-Thr D-Val Pro Gly Ala
G4 Thr D-Val 3-OH-5-Me-Pro Gly Val Thr D-Val Pro Gly Ala
G5 Thr D-Val 3-OH-5-Me-Pro Gly Val cOThr D-Val Pro Gly Ala
G6 Thr D-Val 3-OH-5-Me-Pro Gly Val rThr D-Val Pro Gly Ala
Z1 Thr D-Val 3-OH-5-Me-Pro Gly Val 4-OH-Thr D-Val 4-Oxo-5-Me-Pro Gly Ala
Z3 Thr D-Val 3-OH-5-Me-Pro Gly Val 4-Cl-Thr D-Val 4-Oxo-5-Me-Pro Gly Ala
Z5 Thr D-Val 5-Me-Pro Gly Val 4-Cl-Thr D-Val 4-Oxo-5-Me-Pro Gly Ala
Neo Act A Thr D-Val Pro Gly Val Thr D-Val Pro Gly Ala
Neo Act B Thr D-Val Pro Gly Val Thr D-Val Pro Gly Ala
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1.2 Actinomycin Mechanism of Action 
Actinomycins have three accepted mechanisms of inducing cell death: intercalation 
into pre-melted GC-rich DNA inhibiting mRNA transcription, the transfer of reactive 
oxygen species to the DNA backbone resulting in irreversible damage, and the inhibition 
of topoisomerase I and II.5,6,7,8 The second of these mechanisms is unlikely to be clinically 
relevant due to the required concentration to observe the formation of actinomycin’s 
radical-induced DNA damage; the generation of free radicals requires the an actinomycin 
concentration of ~10-4 M whereas the concentration of actinomycin required to inhibit 
DNA transcription is ~10-8 M.5 Actinomycin’s ability to stimulate double-stranded DNA 
breaks via inhibition of DNA topoisomerases I and II is also observed at a higher 
concentration (1-3 µM) than that required to inhibit DNA transcription.9 However, the 
identification of this class of compound’s ability to form radical species and inhibit 
topoisomerases at all could be relevant in the future diversification of this molecule and 
could be a secondary mechanism of action for actinomycins that appear to be poor DNA 
intercalators. 
The first of these mechanisms has been extensively studied in previous work. 
Actinomycin D has been crystallized with DNA showing the phenoxazinone core 
preferentially intercalated in between the guanine and cytosine residues of the DNA 
double-helix (Figure 1.2.1).10 A strong hydrogen bond is present between the amide N-H 
of amino acid 2 (usually valine) and the carbonyl of amino acid 5 (usually valine or alanine) 
within the same α or β ring to provide the peptidolactone rings with additional rigidity.11 
This rigidity helps align the threonine residue of each ring (amino acid 5) with the guanine 
residue of the DNA backbone; between these two residues, two hydrogen bonds exist 
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between the guanine 2-amino group and the threonine carbonyl as well as between the 
guanine N(3) nitrogen and the amide N-H of the threonine residue.11 It is likely these 
hydrogen bonds and the pi-orbital stacking interactions that confer actinomycin’s 
specificity to GC regions of DNA12,13 However, hydrogen bonding between acintomycin, 
the DNA backbone, and water are much larger contributors to the overall stability of the 
DNA-actinomycin complex. This structure is stabilized by a total of 152 hydrogen bonds, 
80% of which involve an interaction with water; notable exceptions of this complex that 
could but do not participate in hydrogen bonding are the N(7) imidazole nitrogen of 
guanosine and the carbonyl of amino acid 5 in each peptidolactone ring.11 In this complex, 
the peptidolactone rings rest in the DNA minor groove.14 
The stabilization of this actinomycin-DNA complex helps to inform the mechanism of 
action. Early experiments exploring actinomycin’s relationship to cell toxicity found that 
actinomycin bound to DNA and inhibited RNA synthesis by interfering with the growing 
mRNA from RNA polymerase7,15,16,17,18. Implicit in this proposed mechanism was that 
actinomycin would bind to the most common and available form of DNA, B-DNA.19 
Though actinomycin can bind to B-DNA, it binds more tightly to one chain more tightly 
than another due to approximate two-fold symmetry; x-ray crystallography of  the 
actinomycin D-DNA complex showed that the phenoxazinone-like chromophore is slightly 
twisted like a propeller.11,14 This led Sobell to conclude that actinomycin binds to pre-
melted DNA—or β-DNA—at the premelton, preventing RNA polymerase from moving.14 
This explanation also reveals how actinomycin can interfere with mRNA chain elongation 
without inducing premature mRNA chain termination7. 
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Figure 1.2.1-Stereoviews of Actinomycin D Binding to DNA 
 
 
Stereoviews of the actinomycin D-DNA complex. (A) Viewing into the DNA minor 
groove. (B) Viewing into the DNA minor groove but rotated 90o along the axis of the 
helix.20 
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1.3 Structure-Activity Relationships of Modifications the Actinomycin D  
 The biological activity of various actinomycins has been investigated since the 
discovery of actinomycin D.1 However, scientific standards and practices have changed in 
the nearly 80 years since that discovery; as such, it is very difficult to make direct 
comparisons between different actinomycin congeners that have been tested against 
different cell lines using differing measurement techniques. Table 1.3.1 attempts to 
standardize the activities of 20+ naturally occurring actinomycins by comparing their 
activity to actinomycin D in the same cell type using the same measurement technique. 
From this and other synthetic derivatives of actinomycin, we can draw an informed picture 
of the structure-activity relationships (SAR) of how various chemical moieties effect the 
activity of the actinomycin scaffold.  
 As discussed in Section 1.2, actinomycin’s mechanism of action does not utilize 
the formation of a covalent bond to DNA nor does the binding to DNA change 
actinomycin’s covalent structure. Its dominant biological activity is determined by (1) the 
intercalation of the phenoxazinone core between GC base pairs of DNA and (2) the 
stabilization of that intercalation in the DNA minor grove via hydrogen bonding between 
the actinomycin peptidolactone rings and the DNA backbone.5, 11, 14  
In previous SAR studies, sites around the phenoxazinone core have been altered to 
determine their necessity to the biological activity. It was found that the replacement of the 
2-amino group of the phenoxazinone core (2-NH2) with a hydrogen, hydroxyl, or chloro 
group abolished biological activity;21-24 alkylation or acylation at this site reduces the 
activity by 10-fold relative to actinomycin D.22-23 In the case of the recently discovered 
neo-actinomycins, the addition of  TCA cycle intermediates to form the tetracyclic 5H-
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oxazolo[4,5,b] phenoxazinone chromophore reduces the cytotoxicity by 1000-fold and 
reduces the antibacterial potency by 100-fold.2 It is clear from this collective data that the 
2-NH2 position of the phenoxazinone core requires at least one hydrogen bond donor to 
show any measurable activity. It is also clear that disruption to the planar nature of the core 
via attachment of alkyl chains (as is the case in several synthetic derivatives and the neo-
actinomycins) greatly reduces the activity of the actinomycin derivative.2, 22-23    
Other changes to the phenoxazinone chromophore have also been investigated in 
SAR studies. Replacement of the methyl groups at the 4- and 6- position with hydrogens 
or methoxy groups slightly reduces the biological activity but replacement of the methyl 
groups with the similarly sized CF3 groups eliminates the activity of the actinomycin 
derivative, likely due to pulling electronic density away from the aromatic ring system, 
reducing the ability of the molecule to pi-stack with the GC-DNA base pairs.25-26 
Replacement of these methyl groups with bulkier ethyl groups reduced activity by 30-35% 
while replacement with tert- butyl groups abolished activity;25 these changes are likely the 
result of the addition of steric bulk and the disruption of the planar nature of the 
actinomycin core which prevents the molecule from intercalating between DNA base pairs. 
Furthermore, addition of groups to the 7-position of the phenoxazinone core has been 
investigated. 7-chloroactinomycin and 7-nitroactinomycin show ~50% reduced 
antimicrobial activity when compared to actinomycin D but 7-bromoactinomycin showed 
~50% greater activity; all showed comparable antitumor activity to actinomycin D in 
vivo.27-28 This shows not only that this is perhaps a good site to create actinomycin 
derivatives but also provides additional evidence that actinomycins can behave differently 
in bacteria than in mammalian cells.   
 
9 
 
Several modifications to the peptidolactone rings have also been investigated. 
Swapping the Thr (1a, 1b) residue for a Ser, diaminoproprionic acid, or diaminobutyric 
acid displays ~10% of the antibacterial activity and ~10 fold lower antitumor activity than 
actinomycin D.29-31 Replacement of the proline residue with pipecolic acid yields 
actinomycins with little change in activity.32 Replacement of both methyl valine (5a, 5b) 
residues with methyl leucine produces activity ten times greater than actinomycin D; this 
increase in activity is thought to be caused by more hydrophobic interactions between the 
actinomycin derivative and DNA.33 Symmetry of the molecule does not appear to correlate 
with activity. However, the oxidation state of the amino acids in the peptidolactone chains 
do. Actinomycins with a hydroxyl-proline residue—such as actinomycin Y2—show ~1000 
fold decrease in efficacy, likely due to these molecules inability to easily diffuse past the 
cellular membrane.34-35 Actinomycins with a hydroxyl-β-threonine residue (1b)—such as 
actinomycins Z1 and G3—also showed significantly decreased activity, likely for the same 
reason.36-37 The inclusion of a 4-chlorothreonine residue at 1b does not appear to positively 
or negatively affect biological activity.34-36 To date, no sole threonine (1a) modification in 
the α-ring has been discovered or synthesized.  
Finally, the actinomycin G and Y families contain members with unique structures. 
Both contain a rearranged β-ring resulting in the formation of a true cyclopentapeptide that 
is present in actinomycins G6, Y3, and Y4.35 This type of rearrangement all but abolishes 
the cytotoxicity and antibacterial activity of these molecules. These two families also 
contain actinomycins with β-ring heterocycles which link the group at the 2-NH2 position 
with the protruding methyl group from Thr 1b. In the case of actinomycin G5, the 
heteroatom that links these positions is an oxygen; this particular structure renders the 
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actinomycin molecule weakly cytotoxic and a poor antibiotic.36 However, in actinomycin 
Y5, the heteroatom is a nitrogen; this change appears to completely remove any measurable 
cytotoxicity from the molecule but also appears to alter the molecule’s antibacterial activity 
to make it only 30% less effective than actinomycin D or Y1.35 The activities of these 
molecules—G5, G6, Y3-4, and Y5—are of particular interest to this work due to their 
extreme divergence from the core actinomycin scaffold as well as their unique activity, 
especially in the cases of G5 and Y5.  
This is not an exhaustive examination of all SAR studies done to the actinomycin 
scaffold. It allows for the ability to draw some conclusions about modifications that can 
increase and decrease the biological activity of actinomycins. These conclusions also help 
reinforce the mechanism of action for the actinomycin scaffold.  
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Table 1.3.1-Selected Actinomycins and their Biological Activity as Compared to 
Actinomycin D 
 
Compound Cytotoxicity Antibacterial 
Act D 1.00E+00 1.00E+00 
X0β 1.00E-01 2.50E-01 
F8 1.00E-01 4.50E-01 
F9 5.00E-01 3.50E-01 
X2 8.00E+00 2.00E+00 
C2 1.00E+00 7.00E-01 
C3 7.00E-01 9.50E-01 
Y1 1.07E+00 1.00E+00 
Y2 9.41E-04 6.00E-01 
Y3 1.60E-03 6.43E-04 
Y4 1.60E-04 6.43E-04 
Y5 1.60E-04 7.33E-01 
G2 1.23E+00 9.00E-01 
G3 1.23E-02 9.00E-01 
G4 2.46E-02 n/a 
G5 7.62E-04 3.70E-01 
G6 1.60E-03 0.00E+00 
Z1 2.13E-03 6.24E-02 
Z3 1.60E-02 3.90E+00 
Z5 1.60E-02 1.00E+00 
Neo Act A 2.45E-03 1.56E-02 
Neo Act B 2.80E-04 1.95E-03 
 
Value calculated as a ratio of activity to actinomycin D. Values >1.00E+00 show 
greater activity relative to actinomycin; values <1.00E+00 show less activity relative to 
actinomycin. Denotes a ratio of cytotoxicity and antibacterial activity relative to 
actinomycin D. Unknown cell lines tested for cytotoxicity and antibacterial activity.38 
Denotes a ratio of GI50 (µg/mL) relative to actinomycin D in HM02 colorectal cancer 
cells.35 Denotes a ratio of IC50 (nM) relative to actinomycin D in HCT116 gastrointestinal 
carcinoma.2 Denotes a ratio of inhibition zone size (mm) from 50 µg dissolved onto a 6 
mm disk placed on a lawn of Staphylococcus aureus relative to actinomycin D.2, 35 Denotes 
ratio of MIC (µg/mL) values relative to actinomycin D in Bacillus subtilis.34      
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1.4 Current Uses of Actinomycin 
 Actinomycin D is clinically known as Dactinomycin and is marketed under the 
trademark Cosmegen. Its current clinical applications are to treat Wilms’ Tumor, childhood 
Rhabdomyosarcoma, metastatic nonseminomatous testicular cancer, Ewing’s Sarcoma, 
gestational trophoblastic neoplasia, and regional perfusion in locally recurrent and 
locoregional solid malignancies through intravenous injection .39 Its half-life in a dog is 47 
h with a distribution phase of 3 h.40  Though actinomycin shows efficacy against gram-
positive bacteria, gram-negative bacteria, and some fungi, its toxicity precludes it from 
being clinically approved to treat these types of infections.41 It is believed that the 
mechanism of resistance to actinomycins is the development of a multidrug resistant 
phenotype due to the increased production of P-glycoproteins and other xenobiotic 
channels as well as decreased membrane permeability.40 
The current dosing regiments for the various disease state treated by actinomycin 
D are as follows for adults42:  
-Wilms Tumor, 45 µg/kg IV every 3-6 weeks for up to 26 weeks 
-Rhabdomyosarcoma, 15 mg/kg IV on days one and five every 3-9 weeks for up to 
112 weeks 
-Ewing Sarcoma, 1250 µg/m2 IV once per three weeks for 51 weeks 
-Gestational Trophoblastic Neoplasms, 12 µg/kg IV once per day for five days as a 
single agent for nonmetastatic and low-risk metastatic disease, 500 µg/kg IV on days one 
and two once every two weeks for up to 8 weeks for high-risk metastatic disease 
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-Testicular cancer, 1000 µg/kg IV once every three weeks for 12 weeks as part of 
a cisplatin-based, multiagent combination regimen 
-Locoregional solid malignancies, 50 µg/kg IV once in combination with 
melphalan for lower extremity and pelvis malignancies, 35 µg/kg IV once in combination 
with melphalan for upper extremity malignancies 
-Malignant germ cell tumors of the ovary (off label), 300 µg/m2/day IV for 5 days 
once every four weeks in combination with vincristine and cyclophosphamide 
The cost per injection of actinomycin D (under the brand name Cosmegen) is estimated at 
$1,283.43  
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1.5 Gene Cluster of Actinomycin 
The gene clusters between families of actinomycin can vary greatly in gene number but 
can vary subtly in gene product. For example, the gene cluster for actinomycin X—an iso-
actinomycin—sequenced from Streptomyces antibioticus IMRU 3720, contains 20 coding 
DNA sequences (CDSs) spanning 37.5 kb; contrastingly, the gene cluster for actinomycin 
C—another iso-actinomycin—sequenced from Streptomyces chrysomallus, contains 28 
CDSs spanning 47.8 kb.44-45 The gene cluster found in Streptomyces antibioticus IMRU 
3720 represents the minimal manufacturing machinery required to produce an actinomycin 
molecule (Table 1.5.1).45 The discrepancy in size between the two gene clusters stems 
from the presence of eight doubly occurring orthologues in the actinomycin C gene cluster 
expressed under a second promoter.45 The expansion of the actinomycin gene cluster 
appears to have been caused by a mobile genetic element from a foreign actinomycin 
cluster instead of a duplication of the same genes within a cluster; supporting this 
hypothesis are the insertion sequences (IS) found flanking the gene cluster of actinomycin 
C and a 2.5% difference in G+C content between orthologues within the gene cluster.45-46 
Furthermore, although the two gene clusters contain the same genes, they produce two 
subtly different types of actinomycin, implying that some of the transposed genes are 
inactive.45  
 Though the discovery that the expansion that the actinomycin gene cluster was 
likely due to IS elements, its effects may have been observed for some time in the form of 
aniso-actinomycins. For example, actinomycins from the G, Y, and Z (whose gene clusters 
will be discussed in greater detail in Chapter 3) families all have similar modifications to 
their α- and β-rings but differ in how those modifications are combined between rings.34-
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35, 47 This could have been caused by the mutation and transposition of actinomycin gene 
cluster elements that originated from different actinomycin gene cluster donors. 
Furthermore, the G, Y, and Z families all contain a 4-chlorothreonine unit in the 
actinomycin β-ring.34-36 Likely, genes associated with this type of modification were also 
added to the cluster via IS element. However, it is unclear if each of these insertions was 
made in the same way, which might have led to some gene inactivation/mutation and 
explain some of the β-ring variability among the G, Y, and Z family members, specifically. 
This orientation is visualized in Figure 1.5.1. The gene clusters from these family members 
also contain six non-ribosomal peptide synthetase genes as opposed to the normal four 
observed in Streptomyces anulatus and antibioticus.47 This expansion of NRPS machinery 
could explain the biosynthesis and combination specificity of actinomycin α- and β-rings 
observed in aniso-actinomycin families.  
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Table 1.5.1-Annotated Actinomycin Gene Cluster from Streptomyces antibioticus 
 
Genes in S. 
antibioticus 
Predicted 
Function 
Gene 
orthologues in S. 
chysomallus acm 
gene cluster 
left/right arm 
Protein % 
Identity to 
S. 
chysomallus 
orthologue 
Protein % 
similarity to 
S. 
chrysomallu
s orthologue 
AFM16_363
45 α/β hydrolase    
AFM16_363
50 
Ser/Thr protein 
kinase    
saacmrC UvrA-like protein 
scacmcrC/scacm
Y 87/83 92/90 
saacmrB ABC 2-type transporter scacmrB/scacmX 89/85 95/92 
saacmrA 
ABC 
transporter 
ATPase subunit 
scacmrA/scacm
X 86/83 92/89 
saacmQ 
Siderophore-
interacting 
protein 
scacmQ/scacmV 82/79 89/90 
saacmP 
TetR family 
transcriptional 
regulator 
scacmP/scacmU 77/66 83/72 
saacmO LmbU-like protein scacmO/scacmJ 77/71 84/78 
saacmN Ferredoxin scacmN 73 83 
saacmM Cytochrome P450 scacmM 86 90 
saacmL Methyltransferase scacmL/scacmI 88/82 93/88 
saacmK Kynureninase scacmK/scacmH 84/82 89/92 
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saacmG Tryptophan 2,3-dioxygenase scacmG 78 82 
saacmF Aryl formamidase scacmF 82 86 
saacmE Hypothetical protein scacmE 82 89 
saacmC 
Peptide 
synthetase 
ACMS III 
scacmC 76 83 
saacmB 
Peptide 
synthetase 
ACMS II 
scacmB 72 81 
saacmA 
Peptide 
synthetase 
ACMS I 
scacmA 75 84 
saacmD 
4-MHA carrier 
protein 
AcmACP 
scacmD 75 87 
saacmR MbtH-like protein scacmR 80 90 
saacmS Hypothetical protein scacmS 74 85 
saacmT Hypothetical protein scacmT 73 84 
AFM16_364
55 
Putative alpha-
1,2-
mannosidase 
   
AFM16_364
60 
Threonine 
transporter 
RhtB 
   
 
Putative gene cluster for actinomycin D and its relationship to homologues found in the 
actinomycin C gene cluster 
Abbreviations: ACMS (actinomycin synthetase), 4-MHA (3-hydroxy-4-
methylanthranilic acid. 
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Figure 1.5.1-Visualized Actinomycin C, G, and Y Gene Clusters 
 
 
Figure adapted from Wang et al.47 Genes denoted AcmG6-AcmG9 in the actinomycin G 
gene cluster and Y14-Y17 appear to be transcribed in the opposite direction of the genes 
with which they are believed to associate.  
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1.6 Biosynthesis of Actinomycin 
The biosynthesis of actinomycins has been largely elucidated, though the identity of 
the enzymes responsible has not yet been confirmed for every step. To synthesize the 
initiation unit for the NRPS assembly line, tryptophan is first converted to 4-methyl-3-
hydroxyanthranilic acid (4-MHA).48 The first step in the biosynthesis of this piece is the 
oxidation of tryptophan to N-formylkynurenine catalyzed by tryptophan 2,3-dioxygenase 
followed by removal of the formyl group catalyzed by kynurenine formidase to form 
kynurenine.49-50 This intermediate is then hydroxylated by a kynurenine 3-hydroxylase 
before being converted to 4-methyl-3-hydroxyanthranilic acid catalyzed by kynureninase 
and a methyl transferase.51-52 This biosynthetic mechanism follows a similar one found to 
produce part of nicotinamide adenine dinucleotide (NAD), an essential coenzyme involved 
in redox chemistry in all cells.51 However, no one-pot enzymatic reaction has been 
performed to confirm if these are all of the enzymes required to produce 4-MHA, though 
it is accepted within the literature that this is the biosynthetic scheme used by Streptomyces 
sp. in the construction of actinomycins. (Figure 1.6.1)  
The peptide halves of the actinomycin molecule are synthesized like other non-
ribosomal peptides. The thiolation domain (T; also known as a peptidyl-carrier protein 
abbreviated “PCP”) of each NRPS module is first converted from its inactive “apo” form 
to its active “holo” form by the addition of a 4-phosphopantetheinyl (PPant) group to the 
active site serine. After post-translational modification, a stable thioester bond is formed 
between the T domain and the amino acid selected by the adenylation (A) domain. The 
thioester-linked amino acid is subsequently combined with another T-domain-bound 
amino acid from an adjacent module via nucleophilic attack catalyzed by the condensation 
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(C) domain that lies between them. This combination often results in the creation of an 
amide bond. The peptide continues to grow in this way by being passed from module-to-
module in an assembly-line fashion, receiving one additional amino acid from each T-
domain, until it is cleaved from the NRPS enzyme complex via internal cyclization or 
reduction by the thioesterase domain (TE).53-54 This complex can also contain tailoring 
domains—such as methylation, epimerization, and redox domains—to form non-canonical 
amino acids.54-55  
In the case of actinomycin, once the 4-MHA unit has been synthesized, it is loaded onto 
ACMS I (saacmA in Table 1.5.1) via activation with adenosine triphosphate (ATP) before 
being transferred to the 4-MHA carrier protein (saacmD in Table 1.5.1).56-57  These two 
genes represent the “loading domain” of an NRPS assembly line. The 4-MHA starter unit 
is then passed to ACMS II (saacmB in Table 1.5.1) where it is linked to L-threonine and 
L-valine (later epimerized to D-valine via the ACMS II epimerization domain).58-60 The 
growing peptide chain is then shuttled to ACMS III (saacmC in Table 1.5.1)  where it is 
linked with L-proline, sarcosine (N-methylated glycine), and N-methyl-L-valine; the 
completed pentapeptide is cleaved from ACMS III via internal lactone cyclization 
catalyzed by the thioesterase domain between the threonine hydroxyl group and the 
thioester-bound N-methyl-L-valine.58, 61 Two of the cleaved depsipeptide rings are 
combined by a phenoxazinone synthetase (PHS), although no homologue lies within the 
actinomycin gene cluster.62 It is hypothesized that gene the encoding this enzyme lies 
outside of the gene cluster, perhaps in the phenazinomycin gene cluster, which has also 
been found in some actinomycin-producing Streptomyces sp.63 This biosynthesis is 
depicted in Figure 1.6.2 and 1.6.3. 
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As previously mentioned, aniso-actinomycins deviate slightly in their biosynthesis 
from the process described above. Due to the insertion of actinomycin biosynthetic 
machinery from another actinomycin gene cluster, these aniso-producing strains have the 
ability to produce two different depsipeptide rings—using the same generic NRPS 
chemical logic previously described—that are combined in a 1:1 ratio. It is unclear if the 
additional oxidations, methylations, and halogenations observed in the G-, Y-, and Z-
families occur before the amino acids are loaded onto the NRPS assembly line, while the 
growing peptide chains are attached to the assembly, or after the phenoxazinone synthetase 
has united the α- and β-rings.34-37, 47 However, a new NRPS domain—called the X-
domain—was recently discovered and shown to facilitate the recruitment of various 
tailoring enzymes to the NRPS assembly line.64 Perhaps, these families possess a 
homologue to this domain, though we think such a domain is not responsible for β-ring 
heterocycle formation based on actinomycin core reactivity that is explored in Chapter 2.    
 
 
 
 
 
 
 
 
 
 
 
22 
 
Figure 1.6.1-Biosynthesis of 4-methyl-3-hydroxyanthranilic acid in Actinomycin 
Pathway 
 
 
 
Biosynthetic pathway for the generation of 4-methyl-3-hydroxyanthranilic acid (4-MHA). 
The enzymes associated with each numbered step are listed below: 
(1) Tryptophan 2,3-dioxygenase (EC 1.13.11.11) 
(2) Kynurenine formamidase (EC 3.5.1.9) 
(3) Kynurenine 3-hydroxylase (EC 1.14.13.9) 
(4) 3-hydroxy-kyreninase/kynureninase (EC 3.7.1.3) and C-methyltransferase (no 
enzyme commissioner number listed); *likely in this order  
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Figure 1.6.2-Visualized Assembly-line Construction of Actinomycin D on Non-
Ribosomal Peptide Synthetase 
 
 
 
Biosynthetic assembly of each half of actinomycin D on the Non-Ribosomal Peptide 
Synthetase. The enzyme domain legend is listed below: 
 
A: Adenylation Domain 
T: Thiolation Domain (peptidyl-carrier protein abbreviated “PCP”) 
C: Condensation Domain 
E: Epimerization Domain 
M: Methylation Domain 
Te: Thioesterase Domain 
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Figure 1.6.3-Proposed Final Step in Actinomycin Biosynthesis 
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Combination of the identical halves of actinomycin D by phenoxazinone synthetase. To 
date, the gene responsible for this unification has not be elucidated within the actinomycin 
gene cluster.  
 
 
 
 
 
 
 
 
 
 
25 
 
Chapter 2: Synthesis of Phenoxazinone-Like “Actinocin” Core and Determination 
of Its Physical Properties 
 
2.1 Introduction 
 Previously, it was speculated that the β-ring heterocycle observed in actinomycin 
Y5 was formed via an intramolecular SN2-style reaction.35 However, it was our belief that, 
if this were the mechanism of heterocycle formation, this structural motif would be more 
prevalent within the actinomycin Y family. Furthermore, based on the aromatic 
environment in which the proposed nucleophile existed, it was unclear just how reactive 
this phenoxazinone-core aniline (position 2-NH2 in Figure 1.1.1) would be.65 
 We decided to test the reactivity of this position by building a model system. We 
chose to approximate “reactivity” by determining the pKa of the phenoxazinone-core 
aniline by exposing it to a variety of pH conditions due to our assumption that if the electron 
density of this particular aniline group were available to make a nucleophilic attack from 
2-NH2 to Thr 1b in Figure 1.1.1, it would also be available to donate/accept a proton and 
because the pKa of the molecule aniline is 4.63.65 We felt this was appropriate because pH 
is related to pKa through the Henderson-Hasselbach equation and because pKa itself 
denotes the equilibrium constant between an acid and its conjugate base, providing a 
quantitative value for the conditions under which this chemical reaction occurs.66  
 Should the 2-NH2 of methyl actinocin prove reactive, we would try several reaction 
conditions attempting to alkylate that position. The goal was to attempt to recreate the type 
of intramolecular alkylation that would have to occur in β-ring heterocycle containing 
actinomycins if the structural motif were formed via this SN2 mechanism.  
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2.2 Methods 
Experiments confirmed by LC/MS in this chapter were done so utilizing an Agilent Eclipse 
XDB-C18 10mm column attached to an Agilent Technologies 6120 Quadrupole LC/MS. 
The gradient used was 0.4 mL/min flow rate beginning with a ratio of 95:5 water: 
acetonitrile, increasing to 0:100 water: acetonitrile over 16 min. This ratio was held for 
four minutes before reverting back to a 95:5 water: acetonitrile ratio over the next minute. 
This ratio was held for the remaining four minutes.  
Synthesis of Methyl Actinocin 
 The total synthesis of our model is depicted in Figure 2.2.1(a) (1) 3-hydroxy-4-
methyl nitrobenzoic acid (0.25g) was dissolved in 20 mL of anhydrous methanol in a 50 
mL round bottom flask. Two mL of thionyl chloride was added dropwise with stirring. The 
mixture was heated to 60oC under a reflux condenser and left to react overnight. The 
product, 3-hydroxy-4-methyl-2-nitrobenzoic acid methyl ester, was extracted by adding 
ethyl acetate and washing the organic layer mixture twice with saturated sodium 
bicarbonate, twice with brine, and once with water. The organic layer was dried with 
sodium sulfate and concentrated in vacuo. 
(2) To a clean, dry 50 mL double-necked round bottom flask, a few spatulas of 
palladium on activated carbon were added. The flask was then sealed and the air was 
removed and replaced by nitrogen gas. 3-hydroxy-4-methyl-2-nitrobenzoic acid methyl 
ester was dissolved in 20 mL anhydrous methanol and injected into the sealed flask. 
Hydrogen gas was then bubbled into the mixture at room temperature. The reaction was 
left under hydrogen gas for 48 hours. The palladium on activated carbon was removed by 
vacuum filtration through celite.  
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(3) The resulting 2-amino-3-hydroxy-4-methylbenzoate was dissolved in 20 mL 
methanol. Then, 1.10g of potassium ferricyanide was dissolved into 0.067M potassium 
phosphate buffer and added to the mixture followed by the addition of 1.4 mL of 2M 
sodium hydroxide to adjust the pH to ~8. The solution was wrapped in foil and placed 
under nitrogen balloon for 16 h. To extract the organic product, ethyl acetate and water 
were added and the organic layer was extracted. The organic layer was washed with brine 
and then dried with sodium sulfate before being concentrated in vacuo. The resulting red-
orange solid was then subjected to a flash chromatography column (3:1 hexanes:ethyl 
acetate) to purify the resulting dimethyl 2-amino-4,6-dimethyl-3-oxo-3H-phenoxazinone-
1,9-dicarboxylate.67-68 This structure was confirmed by LCMS (Figure 2.2.1 (b)) 
Determination of Methyl Actinocin pKa 
 Twenty-two 0.05M phosphate buffers were made and the pH of each was adjusted 
to be roughly half a unit apart spanning the range pH 1-11.5. A 0.05 M methyl actinocin 
solution in methanol was also made. Eighty µL of methyl actinocin solution was added to 
920 µL of each phosphate buffer in a 10.00 mm quartz cuvette.   
We, then, measured each of our cuvette mixtures at the pH’s listed in Figure 2.3.3 
and noted the absorbance. This was plotted and fit to a polynomial trend line regression 
with the goal of determining the inflection points of these curves. The inflection point is 
important because it is the experimental solution to the Henderson-Hasselbach equation at 
which pH=pKa.66 
Alkylation of Methyl Actinocin 
 The complete list of reaction conditions is outlined in Figure 2.2.2(a)-(c), however 
only one was successful. A deep eutectic solvent (DES) was prepared by mixing 14 mL of 
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urea (18.48g, 2 mol, in 14 mL water) with 7 mL choline chloride (7.63g, 1 mol, in 7 mL 
water); this mixture was heated to 74oC until the solution became clear.69 Once the solution 
was cooled to room temperature, 9 mL of it was added to a 50 mL round bottom flask along 
with 1.94x10-5 mol methyl actinocin (dissolved in 1 mL methanol) and 1.56x10-5 mol (1.64 
µL) of 1-chlorobutane. The mixture was heated to 50oC overnight. Organics were extracted 
from water with ethyl acetate; this organic layer was dried with sodium sulfate and 
concentrated in vacuo. Success of the reaction was confirmed by LC/MS (Figure 2.3.2).   
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Figure 2.2.1(a)-Synthesis Scheme for Methyl Actinocin 
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Figure 2.2.1(b)-LC/MS Trace of Methyl Actinocin 
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Figure 2.2.2-Attempted Methyl Actinocin Alkylation Conditions 
 
(a) 
 
Approx. 58 mg (1.63x10-4 mol) was dissolved in 15 mL methanol. Three mL of that 
mixture was added to 5 mL water, 5 mL acetonitrile, 250 µL triethyl amine, and 1 mL 1-
chlorobutane. The mixture was heated to 60oC overnight. Organics were extracted with 
methanol and dried with sodium sulfate before being concentrated in vacuo. The resulting 
residue was subjected to LC/MS; no reaction observed.  
(b) 
 
 
Approx. 10x acetyl chloride was added slowly to ~50 mg methyl actinocin dissolved in 10 
mL anhydrous dichloromethane with 10x trimethylamine also added. The reaction was 
stirred at room temperature for 30 min. The reaction mixture was extracted with ethyl 
acetate and water. The organic layer was dried with sodium sulfate and concentrated in 
vacuo. The resulting residue was subjected to LC/MS; no reaction observed.  
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(c) 
 
A deep eutectic solvent (DES) was prepared by mixing 14 mL of urea (18.48g, 2 mol, in 
14 mL water) with 7 mL choline chloride (7.63g, 1 mol, in 7 mL water); this mixture was 
heated to 74oC until the solution became clear.69 Once the solution was cooled to room 
temperature, 9 mL of it was added to a 50 mL round bottom flask along with 1.94x10-5 mol 
methyl actinocin (dissolved in 1 mL methanol) and 1.56x10-5 mol (1.64 µL) of 1-
chlorobutane. The mixture was heated to 50oC overnight. Organics were extracted from 
water with ethyl acetate; this organic layer was dried with sodium sulfate and concentrated 
in vacuo. Success of the reaction was confirmed by LC/MS 
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2.3 Results and Discussion 
Synthesis of Methyl Actinocin and pKa Determination 
The final product, dubbed “methyl actinocin”, was to have the exact same aromatic 
core without the complication of the depsipeptide rings; these were simply approximated 
with a methyl group that also served as a way to isolate the phenoxazinone-core aniline as 
the only pH sensitive group in our model system.  
 We, then, determined the wavelength at which the model would show the greatest 
variance in UV absorption across the pH range tested. The UV absorption was scanned at 
all wavelengths for pH = 1, 1.5, 5.5, 6, 10.5, and 11 (Figure 2.3.1 and Figure 2.3.2). From 
this analysis, we determined that 340 nm was the best wavelength to measure changes in 
absorbance. To our surprise, when we measured the absorbance of the methyl actinocin in 
the various phosphate buffers at 340 nm, two inflection points were revealed, implying that 
this position could donate two protons. Furthermore, solving for the trend line equations 
generated from the curves in Figure 2.3.3 yields the pKa values 2.976 and 8.429, indicating 
that above pH 8.5, the 2-NH2 group of methyl actinocin carries a negative charge and is 
likely to be very nucleophilic.  
 Foreshadowing information that will be presented in Chapter 3, we, also, find it 
extremely significant that the largest shifts in UV absorbance that correspond to reactivity 
at the 2-NH2 position of methyl actinocin occur between 300-350 nm. It is likely that such 
UV shifts also occur in actinomycins that have undergone a chemical reaction at this 
position.  
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Alkylation of Methyl Actinocin 
Having determined that the 2-NH2 methyl actinocin is reactive, we tried several 
reaction conditions attempting to alkylate that position. The goal was to attempt to recreate 
the type of intramolecular alkylation that would have to occur in β-ring heterocycle 
containing actinomycins if the structural motif were formed via this SN2 mechanism. 
However, only the reaction utilizing the DES was successful in producing the alkylated 
product (Figure 2.3.4). This could indicate that the 2-NH2 group is more sterically hindered 
than previously believed. It’s also likely the 1-chlorobutane would not be as strong of an 
electrophile in our model as the 1-chlorothreonine being attacked in actinomycins.69-70 
Therefore, though the DES is designed to make amines more reactive, we remain 
comfortable extrapolating the success of this alkylation to postulate the circumstances 
under which an actinomycin would behave similarly.  
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Methyl actinocin scanned over wavelengths 200 – 500 nm at two pH’s < 2.976, 2.976 < pH < 8.249, and  pH > 8.249.  
 
Figure 2.3.1- Total Wavelength Chromatogram of Methyl Actinocin at Multiple pH 
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Figure 2.3.1 zoomed in to highlight the shift in UV absorption between 300 – 350 nm when methyl actinocin is a buffer pH 
> 8.429.  
 
Figure 2.3.2-Total Wavelength Chromatogram of Methyl Actinocin Zoomed In 
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Figure 2.3.3-Determination of Acid Dissociation Constants for Methyl Actinocin 
 
 
Determination of the acid dissociation constant (pKa) for methyl actinocin. pKa values 
were calculated by solving for ‘X’ in the second derivative equations calculated from the 
trend line in each graph. Phosphate buffers made at pH’s 1.05, 1.53, 1.94, 2.52, 3.09, 3.58, 
3.97, 4.55, 5.00, 5.51, 5.89, 6.48, 6.94, 7.48, 7.97, 8.59, 8.65, 9.35, 9.85, 9.93, 10.92, and 
11.45. The effects on methyl actinocin were measured in triplicate. Averages and standard 
deviations shown near inflection points. 
 
 
 
 
 
 
38 
 
 
 
 
 
 
 
 
 
 
 
 
Reaction scheme and LC/MS trace for reaction described in Figure 2.2.2(c). Doubly alkylated product observed at 10.042 min 
using DES.  
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Figure 2.3.4-LC/MS Trace of Successfully Alkylated Methyl Actinocin 
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Chapter 3: Comparative Genomic Analysis of Actinomycin G, Y, and Z Gene 
Clusters 
3.1 Introduction 
 Although the gene clusters for various other actinomycins have been sequenced and 
annotated, the gene cluster producing the actinomycin Y family of compounds in 
Streptomyces GÖ-GS12 had not yet been characterized. We felt this was necessary to test 
our hypothesis that the unique β-ring heterocycle observed in actinomycin Y5 could be 
synthesized through enzymatic means.  
 We also found it odd that no actinomycin containing a β-ring heterocycle was 
observed in the actinomycin Z family considering the family contained nearly all of the 
same structural components of the actinomycin Y family including the 4-chlorothreonine 
moiety. This disparity between family members could help identify the gene responsible 
for the heterocycle formation; if the process was a result of enzymatic transformation, then 
it is possible there would be an obvious difference between the gene clusters if the two 
were aligned. This required us to sequence the genome of the producing strain of the 
actinomycin Z family—Streptomyces fradiae ETH 20675—as the gene cluster responsible 
for producing these compounds was also not reported.  
 We also chose this opportunity of working with these two strains to characterize 
the actinomycins produced by each ourselves. The goals of this endeavor were twofold: (1) 
to accumulate enough actinomycins containing a β-ring heterocycle to confirm or disprove 
its reported unique activity and (2) to identify any novel actinomycin structures, if there 
are any that were missed in previous isolations.  
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3.2 Methods 
Semi-prep HPLC performed Waters 600 controller equipped with a Waters 600 photodiode 
array detector, a Waters 2487 dual absorbance detector, and a Grace Apollo C18 (250mm 
X 4.5 mm, 5µm) column. Isolation gradient used was as follows: a gradient of 100:0 water: 
acetonitrile was increased to 0:100 water acetonitrile over the course of 30 min. This ratio 
was maintained for 5 min before returning to 100:0 water: acetonitrile over the course of 1 
min. This ratio was maintained for the next 3 min. An AB SCIEX Triple TOF 5600 
equipped with a Phenomenex Gemini C18 (100 X 3 mm, 110 Å) column was used to 
determine the HRMS of the actinomycin Y family members and a Agilent 6230 TOF 
LC/MS equipped with a Phenomenex Gemini C18 (100 X 3 mm, 110 Å) column was used 
to determine the HRMS of the actinomycin Z family members. LC/MS gradient is as 
follows: 0.4 mL/min flow rate beginning with a ratio of 95:5 water: acetonitrile, increasing 
to 0:100 water: acetonitrile over 16 min. This ratio was held for four minutes before 
reverting to a 95:5 water: acetonitrile ratio over the next minute. This ratio was held for the 
remaining four minutes. A 400 MHz Varian Inova NMR was used to fully elucidate the 
structures of the actinomycin Y family members.  
Isolation of Streptomyces GÖ-GS12 and Streptomyces fradiae ETH 20675 genomic 
DNA 
 
The genomic DNA of Streptomyces GÖ-GS12 and Streptomyces fradiae ETH 
20675 was isolated by doing the following: cells were grown in 150 mL of GYM media 
(glucose, yeast extract, malt extract) for seven days until sufficient colonies were present. 
Colonies were collected by gravity filtration through an open weave cloth. Colonies were 
resuspended in 5 mL of SET buffer (75 mM NaCl, 25 mM EDTA at pH 8, 20 mM Tris-
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HCl at pH 7.5) in a 50 mL falcon tube and incubated for 1 hr at 37oC with 100 µL of 50 
mg/mL lysozyme solution. Then,  140µL of 20 mg/mL protinase K solution and 600 µL of 
10% SDS solution were added to the mixture and mixed by inversion. Afterwards, the 
mixture was incubated for 2 hrs at 55oC, occasionally mixing by inversion. Following the 
incubation, 2 mL of 5M NaCl was added to the solution and mixed by inversion. The 
solution was placed in a 37oC water bath to cool it to 37oC. Once at the correct temperature, 
5 mL chloroform was added and mixed by inversion for 30 min at room temperature. The 
solution was, then, centrifuged for 15 min at 4000 rpm. The supernatant was transferred to 
a fresh tube and 0.6 vol isopropanol was added and mixed by inversion. After ~3 min, DNA 
was spooled out of the tube using a glass rod and washed with 70% ethanol. The genomic 
DNA was dried under nitrogen gas and redissolved in TE Buffer (25 mM Tris-HCL, pH 8, 
25 mM EDTA, pH 8, 0.3M sucrose).71  
Sequencing of the Genomic DNA, Gene Cluster Assignment, and Cluster Alignment 
The DNA was sequenced using Sanger sequencing and sorted into contigs. We 
searched the gene sequence of each contig with the known gene sequence of acmG2’, a 
gene encoding a large NRPS, to determine which sequences might contain portions of our 
cluster of interest. Additional cosmids were then aligned with the one found to contain the 
actinomycin core biosynthesis gene to determine the contiguous gene sequence between 
cosmids that likely contained the actinomycin gene clusters. Using FRAMEPLOT—which 
takes advantage of the fact Streptomyces sp. overwhelmingly contain a guanine or cytosine 
in the wobble position of a translatable gene—we were able to determine the likely open 
reading frames that yielded the functional gene. These open reading frames were subjected 
to BLAST comparison to determine their putative function (Figure 3.3.1(a)-(c) and Table 
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3.3.1). The actinomycin Y and Z gene clusters were then aligned based on similarities 
between their primary sequences using the computer program ‘Geneious’.   
Isolation of Actinomycin Y and Z family members 
The general growth and isolation procedure for the isolation of actinomycins from 
Streptomyces GÖ-GS12 are as follows: A seed culture of 150 mL of oatmeal medium 
(Quaker Oats ground with mortar and pestle and sterilized by autoclave in Milli-Q water) 
in an Erlenmeyer flask was grown for five days at 28oC shaking at 225 rpm until a slight 
orange color change was observed. Afterwards, 100 µL of seed culture was added to 150 
mL of oatmeal medium spread across several Erlenmeyer flasks (totaling 5 L of oatmeal 
media) with an emphasis on adding at least one visible Streptomyces colony to each flask. 
These flasks were grown for ~10 days at 28oC shaking at 225 rpm until the media became 
a dark orange/red color. After such time, the flasks were emptied and subjected to gravity 
filtration to separate the cell pellet from the supernatant.  
Acetone was added to the cell pellet to lyse and extract metabolites of interest. This 
mixture was stirred at room temperature for 24-48 hours followed by a second gravity 
filtration to remove the lysed cellular debris. The acetone fraction was then concentrated 
in vacuo to yield a large amount of red solid.  
Dichloromethane was added to the supernatant; this mixture was left to stir at room 
temperature for 24-48 hours to extract metabolites of interest. The dichloromethane layer 
was extracted via separatory funnel and concentrated in vacuo.  
The supernatant and pellet extractions were combined by the dissolution of each 
solute in as little methanol as possible. This mixture was subjected to a silica column using 
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the following solvent system: 1.5 column length of 100% CHCl3, 1.5 column length of 
3:97 MeOH:CHCl3, elute with 7:93 MeOH:CHCl3 until yellow/orange color subsides. 
Colored fractions were combined and concentrated in vacuo. Solute was redissolved, again, 
in as little methanol as possible and added slowly to a gravity filtration column containing 
LH-20 sephadex. Orange/ yellow compounds that eluted at the front end of the separation 
(indicating they were the largest of the molecules in the concentrated solute mixture) were 
collected into fractions of 50 mL falcon tubes. Each tube was analyzed by semi-preparative 
HPLC for UV maxima at 240 and 440 nm, indicating a compound that was likely an 
actinomycin. Fractions containing these UV maxima were concentrated and the complex 
mixture was separated by semi-preparative HPLC utilizing the following gradient. HRMS 
and NMR were used to determine the identities of pure peaks, if possible.   
3.3 Results and Discussion 
Gene Annotation and Alignment of Actinomycin Y and Z clusters  
 Using BLAST, we were able to annotate both the actinomycin Y and actinomycin 
Z gene clusters (Table 3.3.1 and Table 3.3.2). These clusters were, then, aligned by 
primary sequence similarity. Our analysis is displayed in Figure 3.3.1. Though we can not 
rule out the possibility of a point mutation to an enzyme within the cluster or the interaction 
with an enzyme outside of the cluster, there are no obvious differences between the two 
clusters such that we would expect the inclusion of actinomycins Y3, Y4, Y5, and Y6 in the 
actinomycin Y family and not find similar members of the actinomycin Z family. 
Therefore, we hypothesized that there are likely undiscovered actinomycin Z family 
members that resembled those in the actinomycin Y family. Specifically, we expected that 
if we attempted to isolate actinomycins from Streptomyces fradiae ETH-20675, we would 
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find actinomycin Z family members resembling those of the actinomycin Y family 
previously listed.  
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Gene Approx. BP Range Within Contig Approx. Size of Gene in BP Proposed Function %  Identity to Closest Reported Homologue
Y1 6109-5666 444 Deaminase/Reductase 95% Strep. sclerotialus
Y2 7427-6405 1023 Oleoyl-ACP hydrolase 52% Strep. albus
Y3 8007-7489 519 Hypothetical Protein 94% Strep. flavovaribilis , 91% Strep. iakyrus
Y4 8058-8918 861 2,3-Tryptophan dioxygenase 97% Strep. flavovaribilis
Y5 9876-9439 438 O-methyltransferase 94% Strep. flavovaribilis , 92% Strep. iakyrus
Y6 10757-10089 669 LbmU-like protein 96% Strep. flavovaribilis , 94% Strep. iakyrus
Y7 12095-11280 816 Siderophore interacting domain 91% Strep. flavovaribilis
Y8 25039-12305 12735 ACMSIII 94% Strep. flavovaribilis , 90% Strep. iakyrus
Y9 32790-25039 7752 ACMSII 92% Strep. flavovaribilis , 87% Strep. iakyrus
Y10 34547-33849 699 Long chanin fatty acid-CoA ligase 94% Strep. iakyrus
Y11 34837-34433 405 4-MHA carrier 94% Strep. iakyrus
Y12 36079-35291 789 ABC-type multidrug transporter 97% Strep. flavovaribilis , 92% Strep. iakyrus
Y13 37702-37241 462 TetR transcriptional regulator 96% Strep. flavovaribilis , 92% Strep. iakyrus
Y14 38912-37755 1158 Bifunctional phosphoglucose/phosphomanose isomerase 96% Strep. iakyrus
Y15 39649-38906 744 SDR_c superfamily, oxoreductase, dehydrogenase 96% Strep. iakyrus
Y16 40909-39713 1197 CypC cytochrome P450 94% Strep. iakyrus
Y17 42064-41048 1017 Non-heme alpha-ketogluterate halogenase 97% Strep. flavovaribilis , 95% Strep. iakyrus
Y18 42000-50300 8301 ACMS II 90% Strep. iakyrus
Y19 ~12kb (between contigs) ACMSIII 93% Strep. flavovaribilis , 91% Strep. iakyrus
Y20 3187-2347 840 Aryl hydrolase 88% Strep. flavovaribilis , 92% Strep. iakyrus
Y21 4563-3297 1266 Kynureninase 99% Strep. flavovaribilis , 93% Strep. iakyrus
Y22 5707-4550 1158 Na/H antiporter 92% Strep. iakyrus
Y23 5949-6191 243 MbtH Protein 99% Strep. iakyrus
Y24 6203-6754 552 Hypothetical Protein 93% Strep. flavovaribilis
Y25 7400-6888 512 Hypothetical Protein 96% Strep. flavovaribilis , 94% Strep. iakyrus
Y26 Cyp450 96% Strep. flavovaribilis
Location of each gene, its proposed enzymatic product, and its closest homologues. Gene found on Contig 00116; Gene 
found on Contig 00117. We attempted to construct a similar table for the actinomycin Z but the top BLAST search result 
was consistently from the actinomycin G cluster with no proposed function. 
Table 3.3.1-Gene Annotations for Actinomycin Y Gene Cluster 
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Figure 3.3.1(a)-Partial Sequence Alignment of Actinomycin Y and Z Gene Clusters 
 
 
 
 
 
 
 
Partial sequence alignment of actinomycin Y and actinomycin Z gene clusters with 
statistics highlighting their similarities. 
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Figure 3.3.1(b)- Partial Sequence Alignment of Actinomycin Y and Z Gene Clusters 
 
 
 
 
 
 
 
Partial sequence alignment of actinomycin Y and actinomycin Z gene clusters with 
statistics highlighting their similarities. 
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Figure 3.3.1(c)- Partial Sequence Alignment of Actinomycin Y and Z Gene Clusters 
 
 
 
 
 
 
 
 
Partial sequence alignment of actinomycin Y and actinomycin Z gene clusters with 
statistics highlighting their similarities. 
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Isolation and Characterization of Novel Actinomycin Y Family Members  
We were able to isolate four new actinomycin Y-family members. Of particular 
interest to us during the isolation of actinomycins from Streptomyces GÖ-GS12 were 
compounds that contained UV maxima at 240nm, 440nm and a small but noticeable UV 
absorption spike ~308nm because no previous actinomycin had been reported with 
noteworthy UV absorption in that range of light. We felt that this change in absorption 
could indicate the formation of novel motif within the actinomycins. The previously 
discovered actinomycin Zp was also isolated for the first time Streptomyces GÖ-GS12.37 
The structures of these compounds are listed in Figure 3.3.2.  
The most interesting actinomycin discovered was named actinomycin Y6, which 
contains both a rearranged β-ring and a β-ring heterocycle. The presence of the β-ring 
heterocycle means there is something bound to the 2-NH2 position of the phenoxazinone 
core, not unlike what was tested in Chapter 2. Similar to what we observed when we 
determined methyl actinocin was in a charged state, actinomycin Y6 has a UV spike at 
~308nm. This supports our hypothesis that binding at the 2-NH2 position of the 
phenoxazinone-core creates a new UV maximum between 300-340 nm. Y6 also represents 
a mechanistic oddity; because the rearranged core is made via two-fold acyl shift and such 
a mechanism removes the electrophile in the proposed SN2 attack to create the β-ring 
heterocycle, what is the 2-NH2 phenoxazinone group attacking on Y3 to create Y6?72 In 
Figure 3.3.3, we outline a possible mechanism for this to occur wherein the protruding 
hydroxyl group is eliminated to form an α,β-unsaturated amide with the depsipeptide ring 
followed by a Michael-like addition to β-position of the unsaturated amide yielding Y6. 
Nucleophiles that attack via Michael addition tend to be “softer”; it would certainly follow 
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chemical logic to suggest that the actinomycin core aniline would be tied electronically to 
the three-ring aromatic system, spreading out the group’s electronic density, thereby 
making the group “softer” than a typical aniline group.73  
While Y6 appears to be a hybrid structure of Y3 and Y5, the three compounds take 
different shapes when bound to DNA (Figure 3.3.4). Using actinomycin D as the standard 
shape for the binding to DNA of these molecules, it is clear that a rearrangement to the 
actinomycin core takes the β-ring out of the plane of proper for DNA binding (shown in 
yellow, representing Y3). However, if this rearranged core undergoes intramolecular 
cyclization to create the β-ring heterocycle (shown in green, representing Y6), the β-ring is 
brought back into the correct plane for DNA binding, but position of the α- and β-rings is 
greatly different from actinomycin D, appearing to form a more compact shape. This shape 
is further compacted if the β-ring rearrangement is removed and only the β-ring heterocycle 
remains (shown in red, representing Y5). We believe it is possible that this constricted 
shape could yield different activity for this molecule as compared to the remaining known 
actinomycins.  
Among the four new actinomycins discovered was actinomycin Y7, which contains 
a 4-hydroxythreonine moiety.37 This molecule was one that we had expected to find during 
our isolation of Streptomyces GÖ-GS12 metabolites because a similar molecule were found 
in the closely related actininomycin Z family: actinomycin Z1.36 This molecule also 
represented something of a “missing link” in the actinomycin Y family: in order to undergo 
the two-fold acyl shift that produced actinomycins Y3 and Y4, an actinomycin containing 
a 4-hydroxythronine moiety was necessary, though—until now—none had been reported 
within this family of actinomycins. We felt confident that, due to the similarities in 
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structure, we would find actinomycin Z homologues in the actinomycin Y family and vice 
versa, unless there was a difference between the two gene clusters.  
  
 
52 
 
Figure 3.3.237-Structures of Newly Discovered Actinomycin Y Family Members 
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Figure 3.3.3- Proposed Two-Fold Acyl Shift Mechanism Responsible for the 
Formation of Actinomycins Y3 and Y4 
 
 
 
Proposed mechanism of formation for actinomycins Y3, Y4, and Y6: Shown above is the 
β-ring reacting with itself and a generic base, possibly water. This mechanism appears to 
be thermodynamically driven.35, 72 
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Figure 3.3.4-Guassian Energy Optimization Model of Actinomycins Binding to DNA 
 
 
The structure of actinomycin D is shown in blue line. Actinomycin Y3 containing a 
rearranged β-ring was shown in yellow, Y5 and Y6 containing the additional ring structure 
were shown as red and green lines, respectively. Structures were superimposed by 
chromophore cores, and the structures of Y3, Y5 and Y6 were established and optimized 
using Gaussian program.74  
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Isolation and Characterization of Novel Actinomycin Z Family Members  
More than five “pure” peaks were isolated from semi-preparative HPLC, two of 
which contained the UV spike at ~308 nm of interest. The masses of these peaks—which 
also eluted at similar times to that observed for actinomycin Y6—were [M+H+] 1283.62, 
and 1335.66 respectively dubbed Z6 and Z7.  
While the mass for Z6 (Vial 1; Figure 3.3.5(a)) could be worked into a compound 
containing a β-ring heterocycle, Z7 (Vial 7; Figure 3.4.7(a)) could not. However, the UV 
absorption suggested something was bound to the phenoxazinone-core aniline (position 2-
NH2 in Figure 1.1). Recently, it was discovered that actinomycins could react with 
pyruvate to create neoactinomycins A and B.2 Though no unique UV absorption was 
reported in the discovery of neoactinomycins, through the work previously described in 
Chapter 2, there is a noticeable uptick in absorbance in the ~308 nm range when the 
actinomycin core is exposed to a pH lower than 2.976 and greater than 8.429, likely 
indicating that there is UV shift when the phenoxazinone-core aniline is protonated or 
deprotonated. It would, therefore, stand to reason there is a UV absorption shift into this 
range when there is something bound to this aniline. Therefore, based on HRMS and UV 
absorption, I believe Z7 and contains the same structure as Z3 with the addition of an oxime 
group at position 2-NH2 in Figure 1.1. Unfortunately, we do not have enough of this 
material to do confirm this hypothesis via NMR.  
 Additionally, we were able to observe actinomycin Z compounds with likely 
rearranged β-rings as members of a mixture of compounds present in a total ion 
chromatogram while doing HRMS of isolated peaks from the semi-preparative HPLC done 
during purification. Specifically, we believe the major compound found in Vial 3 (dubbed 
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Z8) (Figure 3.4.7(a)-(k)) contains a rearranged β-ring core due to its mass and lack of 
bioactivity. Figure 3.4.7(k) even provides some evidence of an actinomycin Y6 homologue 
within the actinomycin Z family due to its mass and shift in UV absorbtion.  Therefore, we 
were correct in our hypothesis that the actiniomycin Z contained a nearly identical set of 
members to the actinomycin Y family, several of which were previously undiscovered.  
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Figure 3.3.5(a)-Proposed Structure and Physical Properties of Actinomycin Z Family 
Member Found in Vial 1 
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Chemical Formula: C61H78N12O18
Exact Mass: 1266.56
Molecular Weight: 1267.36
m/z: 1266.56 (100.0%), 1267.56 (66.0%), 1268.56 (21.4%), 
1269.57 (4.6%), 1267.55 (4.4%), 1268.56 (3.7%), 1268.56 (2.9%), 
1269.56 (2.4%)
Elemental Analysis: C, 57.81; H, 6.20; N, 13.26; O, 22.72
O
 
Proposed structure actinomycin Z family member tested as Vial 1 during bioactivity assays 
in Chapter 4. Elution time 22.335 min using described HPLC method.  
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Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV 
profile of metabolite found at 9.920 min using LC/MS gradient and column.  
 
Figure 3.3.5(b)-Total Ion Chromatogram and Total Wavelength Channel for Vial 1  
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Figure 3.3.5(c)-HRMS of Vial 1 at 9.920 min 
 
 
Mass spectrum of metabolite found at 9.920 min.  
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Figure 3.3.5(d)-UV Profile of Vial 1 Peak at 9.920 min 
 
 
UV spectrum of metabolite found at 9.920 min.  
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Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV 
profile of metabolite found at 13.307 min using LC/MS gradient and column. 
 
Figure 3.3.5(e)- Total Ion Chromatogram and Total Wavelength Channel for Vial 1  
 
   
62 
 
Figure 3.3.5(f)- HRMS of Vial 1 at 13.337 min 
 
 
Mass spectrum of metabolite found at 13.307 min. 
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Figure 3.3.5(g)- UV Profile of Vial 1 Peak at 13.337 min 
 
 
UV spectrum of metabolite found at 13.307 min.  
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Figure 3.3.6(a)- Proposed Structure and Physical Properties of Actinomycin Z Family 
Member Found in Vial 2 
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Chemical Formula: C62H82N12O18
Exact Mass: 1282.59
Molecular Weight: 1283.40
m/z: 1282.59 (100.0%), 1283.59 (67.1%), 1284.59 (22.1%), 1283.58 
(4.4%), 1285.60 (4.0%), 1284.59 (3.7%), 1284.59 (3.0%), 1285.59 
(2.5%)
Elemental Analysis: C, 58.02; H, 6.44; N, 13.10; O, 22.44
HO
 
Proposed structure actinomycin Z family member tested as Vial 2 during bioactivity assays 
in Chapter 4. Elution time 25.251 min using described HPLC method. 
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Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV 
profile of metabolite found at 9.967 min using LC/MS gradient and column. 
 
Figure 3.3.6(b)- Total Ion Chromatogram and Total Wavelength Channel for Vial 2  
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Figure 3.3.6(c)- HRMS of Vial 2 at 9.967 min 
 
 
Mass spectrum of metabolite found at 9.967 min. 
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Figure 3.3.6(d)- UV Profile of Vial 2 Peak at 9.967 min 
 
 
UV spectrum of metabolite found at 9.967 min.  
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Figure 3.3.7(a)- Proposed Structure and Physical Properties of Actinomycin Z Family 
Member Found in Vial 3 
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Chemical Formula: C62H84N12O19
Exact Mass: 1300.60
Molecular Weight: 1301.42
m/z: 1300.60 (100.0%), 1301.60 (67.1%), 1302.60 (22.1%), 1301.59 (4.4%), 1303.61 (4.0%), 1302.60 (3.9%), 
1302.60 (3.0%), 1303.61 (2.6%)
Elemental Analysis: C, 57.22; H, 6.51; N, 12.92; O, 23.36
 
Proposed structure actinomycin Z family member tested as Vial 3 during bioactivity assays 
in Chapter 4. Elution time 25.251 min using described HPLC method. 
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Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV 
profile of metabolite found at 11.537 min using LC/MS gradient and column. 
 
Figure 3.3.7(b)- Total Ion Chromatogram and Total Wavelength Channel for Vial 3 
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Figure 3.3.7(c)- HRMS of Vial 3 at 11.537 min 
 
 
Mass spectrum of metabolite found at 11.537 min. 
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Figure 3.4.3(d)- UV Profile of Vial 3 Peak at 11.537 min 
 
 
UV spectrum of metabolite found at 11.537 min. 
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Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV 
profile of metabolite found at 12.097 min using LC/MS gradient and column. 
 
Figure 3.3.7(e)- Total Ion Chromatogram and Total Wavelength Channel for Vial 3 
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Figure 3.3.7(f)- HRMS of Vial 3 at 12.097 min 
 
 
Mass spectrum of metabolite found at 12.097 min. 
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Figure 3.3.7(g)- UV Profile of Vial 3 Peak at 12.097 min 
 
 
UV spectrum of metabolite found at 12.097 min. 
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Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV 
profile of metabolite found at 13.377 min using LC/MS gradient and column. 
Figure 3.3.7(h)- Total Ion Chromatogram and Total Wavelength Channel for Vial 3 
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Figure 3.3.7(i)- HRMS of Vial 3 at 13.377 min 
 
 
Mass spectrum of metabolite found at 13.377min. 
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Figure 3.3.7(j)- UV Profile of Vial 3 Peak at 13.377 min 
 
 
UV spectrum of metabolite found at 13.377 min. 
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UV spectrum of metabolite found at 11.537 min zoomed in to reveal new UV maximum between 300-340 nm. 
 
Figure 3.3.7(k)- UV Profile of Vial 3 Peak at 13.377 min Zoomed In 
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Figure 3.3.8(a)- Proposed Structure and Physical Properties of Actinomycin Z Family 
Member Found in Vial 4 
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Chemical Formula: C62H84N12O19
Exact Mass: 1300.60
Molecular Weight: 1301.42
m/z: 1300.60 (100.0%), 1301.60 (67.1%), 1302.60 (22.1%), 1301.59 
(4.4%), 1303.61 (4.0%), 1302.60 (3.9%), 1302.60 (3.0%), 1303.61 
(2.6%)
Elemental Analysis: C, 57.22; H, 6.51; N, 12.92; O, 23.36
 
Proposed structure actinomycin Z family member tested as Vial 4 during bioactivity assays 
in Chapter 4. Elution time 26.518 min using described HPLC method. 
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Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV 
profile of metabolite found at 10.041 min using LC/MS gradient and column. 
 
Figure 3.3.8(b)- Total Ion Chromatogram and Total Wavelength Channel for Vial 4 
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Figure 3.3.8(c)- HRMS of Vial 4 at 10.041 min 
 
 
Mass spectrum of metabolite found at 10.041 min. 
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Figure 3.3.8(d)- UV Profile of Vial 4 Peak at 10.041 min 
 
 
UV spectrum of metabolite found at 10.041 min. 
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Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV 
profile of metabolite found at 11.614 min using LC/MS gradient and column. 
 
Figure 3.3.8(e)- Total Ion Chromatogram and Total Wavelength Channel for Vial 4 
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Figure 3.3.8(f)- HRMS of Vial 4 at 11.614 min 
 
 
Mass spectrum of metabolite found at 11.614 min. 
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Figure 3.3.8(g)- UV Profile of Vial 4 Peak at 11.614 min 
 
 
UV spectrum of metabolite found at 11.614 min. 
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Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV 
profile of metabolite found at 12.100 min using LC/MS gradient and column. 
 
Figure 3.3.8(h)- Total Ion Chromatogram and Total Wavelength Channel for Vial 4 
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Figure 3.3.8(i)- HRMS of Vial 4 at 12.100 min 
 
 
Mass spectrum of metabolite found at 12.100 min. 
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Figure 3.3.8(j)- UV Profile of Vial 4 Peak at 12.100 min 
 
 
UV spectrum of metabolite found at 12.100 min. 
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Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV 
profile of metabolite found at 14.094 min using LC/MS gradient and column.  
 
Figure 3.3.8(k)- Total Ion Chromatogram and Total Wavelength Channel for Vial 4 
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Figure 3.3.8(l)- HRMS of Vial 4 at 14.094 min 
 
 
Mass spectrum of metabolite found at 14.094 min. 
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Figure 3.3.8(m)- UV Profile of Vial 4 Peak at 14.094 min 
 
 
UV spectrum of metabolite found at 14.094 min. 
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Figure 3.3.9(a)- Proposed Structure and Physical Properties of Actinomycin Z Family 
Member Found in Vial 5 
  
 
 
Proposed structure actinomycin Z family member tested as Vial 5 during bioactivity assays 
in Chapter 4. Elution time 30.099 min using described HPLC method. 
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Chemical Formula: C62H84N12O17
Exact Mass: 1268.61
Molecular Weight: 1269.42
m/z: 1268.61 (100.0%), 1269.61 (67.1%), 1270.61 (22.1%), 1269.60 
(4.4%), 1271.62 (4.0%), 1270.61 (3.5%), 1270.61 (3.0%), 1271.62 
(2.3%)
Elemental Analysis: C, 58.66; H, 6.67; N, 13.24; O, 21.43
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Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV 
profile of metabolite found at 10.043 min using LC/MS gradient and column 
Figure 3.3.9(b)- Total Ion Chromatogram and Total Wavelength Channel for Vial 5 
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Figure 3.3.9(c)- HRMS of Vial 5 at 10.043 min 
 
 
Mass spectrum of metabolite found at 10.043 min. 
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Figure 3.3.9(d)- UV Profile of Vial 5 Peak at 10.043 min 
 
 
UV spectrum of metabolite found at 10.043 min. 
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UV spectrum of metabolite found at 10.043 min zoomed in to reveal new UV maximum between 300-340 nm. 
 
Figure 3.3.9(e)- UV Profile of Vial 5 Peak at 10.043 min Zoomed In 
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Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV 
profile of metabolite found at 13.696 min using LC/MS gradient and column. 
 
Figure 3.3.9(f)- Total Ion Chromatogram and Total Wavelength Channel for Vial 5 
 
    
98 
 
Figure 3.3.9(g)- HRMS of Vial 5 at 13.696 min 
 
 
Mass spectrum of metabolite found at 13.696 min. 
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Figure 3.3.9(h)- UV Profile of Vial 5 Peak at 13.696 min 
 
 
UV spectrum of metabolite found at 13.696 min. 
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Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV 
profile of metabolite found at 14.736 min using LC/MS gradient and column. 
 
Figure 3.3.9(i)- Total Ion Chromatogram and Total Wavelength Channel for Vial 5 
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Figure 3.3.9(j)- HRMS of Vial 5 at 14.736 min 
 
 
Mass spectrum of metabolite found at 14.736 min. 
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Figure 3.3.9(k)- UV Profile of Vial 5 Peak at 14.736 min 
 
 
UV spectrum of metabolite found at 14.736 min. 
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UV spectrum of metabolite found at 14.736 min zoomed in to reveal new UV maximum between 300-340 nm.  
 
Figure 3.3.9(l)- UV Profile of Vial 5 Peak at 14.736 min Zoomed In 
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Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV 
profile of metabolite found at 15.989 min using LC/MS gradient and column.  
 
Figure 3.3.9(m)- Total Ion Chromatogram and Total Wavelength Channel for Vial 5 
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Figure 3.3.9(n)- HRMS of Vial 5 at 15.898 min 
 
 
Mass spectrum of metabolite found at 15.898 min. 
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Figure 3.3.9(o)- UV Profile of Vial 5 Peak at 15.898 min 
 
 
UV spectrum of metabolite found at 15.898 min. 
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Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV 
profile of metabolite found at 16.500 min using LC/MS gradient and column. 
 
Figure 3.3.9(p)- Total Ion Chromatogram and Total Wavelength Channel for Vial 5 
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Figure 3.4.5(q)- HRMS of Vial 5 at 16.500 min 
 
 
Mass spectrum of metabolite found at 16.500 min. 
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Figure 3.3.9(r)- UV Profile of Vial 5 Peak at 16.500 min 
 
 
UV spectrum of metabolite found at 16.500 min. 
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Figure 3.3.10(a)- Proposed Structure and Physical Properties of Actinomycin Z 
Family Member Found in Vial 6 
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Chemical Formula: C62H83ClN12O17
Exact Mass: 1302.57
Molecular Weight: 1303.86
m/z: 1302.57 (100.0%), 1303.57 (67.1%), 1304.57 (32.0%), 1304.58 
(22.1%), 1305.57 (21.4%), 1306.57 (7.1%), 1305.58 (4.8%), 1303.57 
(4.1%), 1304.57 (3.5%), 1304.57 (3.0%), 1305.58 (2.3%), 1305.56 
(1.4%), 1307.58 (1.3%), 1306.57 (1.1%)
Elemental Analysis: C, 57.11; H, 6.42; Cl, 2.72; N, 12.89; O, 20.86
Cl
 
Proposed structure actinomycin Z family member tested as Vial 6 during bioactivity assays 
in Chapter 4. Elution time 30.779 min using described HPLC method. 
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Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV 
profile of metabolite found at 10.043 min using LC/MS gradient and column. 
 
Figure 3.3.10(b)- Total Ion Chromatogram and Total Wavelength Channel for Vial 6 
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Figure 3.3.10(c)- HRMS of Vial 6 at 10.043 min 
 
 
Mass spectrum of metabolite found at 10.043 min. 
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Figure 3.3.10(d)- UV Profile of Vial 6 Peak at 10.043 min 
 
 
UV spectrum of metabolite found at 10.043 min
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UV spectrum of metabolite found at 10.043 min zoomed in to reveal new UV maximum between 300-340 nm.  
 
Figure 3.3.10(e)- UV Profile of Vial 6 Peak at 10.043 min Zoomed In 
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Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and profile 
of metabolite found at 13.883 min using UV LC/MS gradient and column. 
 
Figure 3.3.10(f)- Total Ion Chromatogram and Total Wavelength Channel for Vial 6 
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Figure 3.3.10(g)- HRMS of Vial 6 at 13.883 min 
 
 
Mass spectrum of metabolite found at 13.883 min. 
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Figure 3.3.10(h)- UV Profile of Vial 6 Peak at 13.883 min 
 
 
UV spectrum of metabolite found at 13.883 min. 
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Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV 
profile of metabolite found at 16.336 min using LC/MS gradient and column. 
 
Figure 3.3.10(i)- Total Ion Chromatogram and Total Wavelength Channel for Vial 6 
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Figure 3.3.10(j)- HRMS of Vial 6 at 16.336 min 
 
 
Mass spectrum of metabolite found at 16.336 min. 
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Figure 3.3.10(k)- UV Profile of Vial 6 Peak at 16.336 min 
 
 
UV spectrum of metabolite found at 16.336min. 
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Figure 3.3.11(a)- Proposed Structure and Physical Properties of Actinomycin Z 
Family Member Found in Vial 7 
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Chemical Formula: C62H83ClN12O19
Exact Mass: 1334.56
Molecular Weight: 1335.86
m/z: 1334.56 (100.0%), 1335.56 (67.1%), 1336.56 (32.0%), 1336.57 
(22.1%), 1337.56 (21.4%), 1338.56 (7.1%), 1337.57 (4.8%), 1335.56 
(4.4%), 1336.56 (3.9%), 1336.56 (3.0%), 1337.57 (2.6%), 1339.57 
(1.5%), 1337.55 (1.4%), 1338.56 (1.2%)
Elemental Analysis: C, 55.75; H, 6.26; Cl, 2.65; N, 12.58; O, 22.76
HO
Cl
OH
 
Proposed structure actinomycin Z family member tested as Vial 7 during bioactivity assays 
in Chapter 4. Elution time 24.370 min using described HPLC method. 
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Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV 
profile of metabolite found at 11.588 min using LC/MS gradient and column. 
 
Figure 3.3.11(b)- Total Ion Chromatogram and Total Wavelength Channel for Vial 7 
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Figure 3.3.11(c)- HRMS of Vial 7 at 11.588 min 
 
 
 
Mass spectrum of metabolite found at 11.588 min. 
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Figure 3.3.11(d)- UV Profile of Vial 7 Peak at 11.588 min 
 
 
UV spectrum of metabolite found at 11.588 min. 
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Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV 
profile of metabolite found at 13.401 min using LC/MS gradient and column. 
 
Figure 3.3.11(e)- Total Ion Chromatogram and Total Wavelength Channel for Vial 7 
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Figure 3.3.11(f)- HRMS of Vial 7 at 13.041 min 
 
 
Mass spectrum of metabolite found at 13.041 min. 
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Figure 3.3.11(g)- UV Profile of Vial 7 Peak at 13.041 min 
 
 
UV spectrum of metabolite found at 13.041 min. 
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Figure 3.3.12(a)- Proposed Structure and Physical Properties of Actinomycin Z 
Family Member Found in Vial 8 
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Chemical Formula: C61H81ClN12O18
Exact Mass: 1304.55
Molecular Weight: 1305.84
m/z: 1304.55 (100.0%), 1305.55 (66.0%), 1306.55 (32.0%), 1306.55 (21.4%), 1307.55 (21.1%), 1308.55 
(6.8%), 1305.55 (4.4%), 1307.56 (3.7%), 1306.55 (3.7%), 1306.55 (2.9%), 1307.56 (2.4%), 1309.56 
(1.5%), 1307.54 (1.4%), 1308.55 (1.2%)
Elemental Analysis: C, 56.11; H, 6.25; Cl, 2.71; N, 12.87; O, 22.05
 
Proposed structure actinomycin Z family member tested as Vial 8 during bioactivity assays 
in Chapter 4. Elution time 25.250 min using described HPLC method. 
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Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV 
profile of metabolite found at 11.782 min using LC/MS gradient and column. 
 
Figure 3.3.12(b)- Total Ion Chromatogram and Total Wavelength Channel for Vial 8 
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Figure 3.3.12(c)- HRMS of Vial 8 at 11.782 min 
 
 
Mass spectrum of metabolite found at 11.782 min. 
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Figure 3.3.12(d)- UV Profile of Vial 7 Peak at 11.782 min 
 
 
UV spectrum of metabolite found at 11.782 min. 
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Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV 
profile of metabolite found at 12.800 min using LC/MS gradient and column. 
 
Figure 3.3.12(e)- Total Ion Chromatogram and Total Wavelength Channel for Vial 8 
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Figure 3.3.12(f)- HRMS of Vial 8 at 12.800 min 
 
 
Mass spectrum of metabolite found at 12.800 min. 
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Figure 3.3.12(g)- UV Profile of Vial 8 Peak at 12.800 min 
 
 
UV spectrum of metabolite found at 12.800 min. 
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Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV 
profile of metabolite found at 13.435 min using LC/MS gradient and column. 
 
Figure 3.3.12(h)- Total Ion Chromatogram and Total Wavelength Channel for Vial 8 
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Figure 3.3.12(i)- HRMS of Vial 8 at 13.435 min 
 
 
Mass spectrum of metabolite found at 13.435 min. 
 
 
 
 
 
 
 
 
    
137 
 
Figure 3.3.12(j)- UV Profile of Vial 8 Peak at 13.435 min 
 
 
UV spectrum of metabolite found at 13.435 min. 
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Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV 
profile of metabolite found at 13.600 min using LC/MS gradient and column. 
 
Figure 3.3.12(k)- Total Ion Chromatogram and Total Wavelength Channel for Vial 8 
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Figure 3.3.12(l)- HRMS of Vial 8 at 13.600 min 
 
 
Mass spectrum of metabolite found at 13.600 min. 
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Figure 3.3.12(m)- UV Profile of Vial 8 Peak at 13.600 min 
 
 
UV spectrum of metabolite found at 13.600 min. 
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UV spectrum of metabolite found at 13.600 min zoomed in to reveal new UV maximum between 300-340 nm. 
 
Figure 3.3.12(n)- UV Profile of Vial 8 Peak at 13.600 min Zoomed In 
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Figure 3.3.13(a)- Proposed Structure and Physical Properties of Actinomycin Z 
Family Member Found in Vial 9 
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Chemical Formula: C62H84N12O19
Exact Mass: 1300.60
Molecular Weight: 1301.42
m/z: 1300.60 (100.0%), 1301.60 (67.1%), 1302.60 (22.1%), 
1301.59 (4.4%), 1303.61 (4.0%), 1302.60 (3.9%), 1302.60 
(3.0%), 1303.61 (2.6%)
Elemental Analysis: C, 57.22; H, 6.51; N, 12.92; O, 23.36
 
Proposed structure actinomycin Z family member tested as Vial 9 during bioactivity assays 
in Chapter 4. Elution time 20.521 min using described HPLC method. 
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Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV 
profile of metabolite found at 9.400 min using LC/MS gradient and column. 
 
Figure 3.3.13(b)- Total Ion Chromatogram and Total Wavelength Channel for Vial 9 
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Figure 3.3.13(c)- HRMS of Vial 9 at 9.400 min 
 
 
Mass spectrum of metabolite found at 9.400 min. 
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Figure 3.3.13(d)- UV Profile of Vial 9 Peak at 9.400 min 
 
 
UV spectrum of metabolite found at 9.400 min. 
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Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV 
profile of metabolite found at 9.764 min using LC/MS gradient and column. 
 
Figure 3.3.13(e)- Total Ion Chromatogram and Total Wavelength Channel for Vial 9 
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Figure 3.3.13(f)- HRMS of Vial 9 at 9.764 min 
 
 
 
 
 
 
 
 
 
 
Mass spectrum of metabolite found at 9.764 min. 
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Figure 3.3.13(g)- UV Profile of Vial 9 Peak at 9.764 min 
 
 
UV spectrum of metabolite found at 9.764 min. 
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Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV 
profile of metabolite found at 9.850 min using LC/MS gradient and column. 
 
Figure 3.3.13(h)- Total Ion Chromatogram and Total Wavelength Channel for Vial 9 
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Figure 3.4.9(i)- HRMS of Vial 9 at 9.850 min 
 
 
Mass spectrum of metabolite found at 9.850 min. 
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Figure 3.3.13(j)- UV Profile of Vial 9 Peak at 9.850 min 
 
 
UV spectrum of metabolite found at 9.850 min. 
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Total Ion Current (TIC) and Total Wavelength Current (TWC) from Agilent 6230 TOF LC/MS. Highlighting mass and UV 
profile of metabolite found at 12.100 min using LC/MS gradient and column. 
 
Figure 3.4.9(k)- Total Ion Chromatogram and Total Wavelength Channel for Vial 9 
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Figure 3.3.13(l)- HRMS of Vial 9 at 12.100 min 
 
 
Mass spectrum of metabolite found at 12.100 min. 
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Figure 3.3.13(m)- UV Profile of Vial 9 Peak at 12.100 min 
 
 
UV spectrum of metabolite found at 12.100 min. 
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Chapter 4: Analysis of Biological Activity of Newly Isolated Actinomycins and 
Instigation of β-Ring Heterocycle Formation 
 
4.1 Introduction 
 As has been described in Section 1.3, many actinomycin congeners have been 
discovered, each with their own small difference. These compounds had their biological 
activities compared to actinomycin D in Table 1.3.1, which also compares which 
differences to the actinomycin scaffold improve or reduce the biological activity of these 
molecules. We decided to perform a similar study of the biological activity of our newly 
discovered actinomycins to add to enhance this area of study.  
However, the compound that had garnered the most interest for its unique activity—
actinomycin Y5—still eluded us. Because we had such difficulty isolating actinomycin Y5, 
we decided to synthesize a model compound that we could make cheaply and abundantly. 
We also hoped that the synthesis of such a model would allow us to test various reaction 
conditions to attempt to form the β-ring heterocycle that we believe is imperative to the 
molecules’ peculiar activity. These reaction conditions would also serve as a barometer for 
how “likely” the spontaneous formation of this heterocycle would be, given the power of 
the reagents added. We also hoped to use these same reaction conditions to stimulate the 
formation of a β-ring heterocycle in 4-chlorothreonine containing actinomycins, such as 
actinomycin Z5.  
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4.2 Methods 
Experiments confirmed by LC/MS in this chapter were done so utilizing an Agilent 
Eclipse XDB-C18 10mm column attached to an Agilent Technologies 6120 Quadrupole 
LC/MS and an AB SCIEX Triple TOF 5600 equipped with a Phenomenex Gemini C18 
(100 X 3 mm, 110 Å) column. The same gradient was used for both: 0.4 mL/min flow rate 
beginning with a ratio of 95:5 water: acetonitrile, increasing to 0:100 water: acetonitrile 
over 16 min. This ratio was held for four minutes before reverting to a 95:5 water: 
acetonitrile ratio over the next minute. This ratio was held for the remaining four minutes. 
A 400 MHz Varian Inova NMR was used to fully elucidate the structure of 3-chloro-1-
propanol ester actinocin. 
Determination of actinomycins Y and Z minimum inhibitory concentration (MIC) 
The MIC of the newly discovered actinomycin Y6-Y9 and all isolated actinomycin 
Z compounds was determined as follows. The bacterial strains Staphylococcus aureus 
ATCC 6538, Micrococcus lutens ATCC 15307, Bacillus subtilis ATCC 6633, Salmonella 
enterica ATCC 10708, Escherichia coli ATCC 12345 and Mycobacterium aurum ATCC 
23366 as well as the fungal strain Saccharomyces cerevisiae ATCC 204508 were selected 
as representative strains to assess the antimicrobial activity of these compounds. S. aureus 
and M. lutens were grown in tryptic soy broth (BD211825), while B. subtilis and E.coli 
were grown in LB medium BD244620), and S. enterica was grown in nutrient broth (BD 
234000). Middlebrook 7H9 with OADC enrichment (Sigma Aldrich M0178-500G) was 
used to grow M. aurum and YAPD (ATCC medium number 1069) was used to grow S. 
cerevisie. These strains were grown individually in 5 mL of their respective mediums for 
16 h at 37oC with shaking (250 rpm). A 100 µL aliquot of fully grown culture was diluted 
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using the same respective sterile medium to an OD600 ~0.1. Aliquots (160 µL) of each 
diluted culture were added to individual wells of a 96-well plate along with 2 µL of serially 
diluted test compound. These serial dilutions began from an ~10 µg/mL stock solution and 
each was a tenfold dilution of the previous mixture. The range of maximum final 
concentrations within each well were maintained to assess antimicrobial activity of these 
compounds compared to the negative control vehicle (DMSO) and the ppositive controls 
(rifampicin and ciprofloxacin for M. aurum, amphotericin B for S. cerevisiae, and 
kanamycin for the remaining microorganisms tested). These culture plates were incubated 
at 20-37oC for 16-48 h with shaking (160 rpm). Afterwards, the OD600 values of each well 
was measured by FLUOstar Omega scanning microplate spectrophotometer (BMG 
Labtech). These OD600 values were normalized to the negative control wells containing no 
drug with 100% microorganism viability. The minimum concentration of the tested 
compound that prevented microorganism growth was noted as the MIC.37, 75-76 
Determination of actinomycins Y and Z cytotoxic potency 
These compounds were also tested for their cytotoxicity against PC3 human 
prostate cancer cells and A549 human lung non-small-cell carcinoma cells. This was done 
using a resazurin-based cytotoxicity assay (or AlamarBlue assay). Cytotoxcity of the tested 
compounds is assessed by measuring the reduction of resazurin (7-hydroxy-10-
oxidophenoazin-10-ium-3-one) to its fluorescent product resorufin. A549 and PC3 cells, 
purchased from ATCC (Manassas, VA, USA) were grown in DMEM/F-12 Kaighn’s 
modification and MEM/EBSS media (Thermo Scientific Hyclone, Logan, UT, USA), 
respectively. To the media, 10% heat-inactivated fetal bovine serum (FBS), 100 U/mL 
penicillin, 100 µg/mL streptomycin, and 2mM L-glutamine was added. Cells were seeded 
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at a density of 5 x 103 cells per well onto 96-well culture plates containing a clear bottom 
(Corning, NY, USA). These cells were incubated at 37oC for 24 h in a humidified 
atmosphere containing 5% CO2. Afterwards, the cells were exposed to the tested 
compounds for 2 days (positive controls: 1.5 mM hydrogen peroxide and 10 µg/mL 
actinomycin D). After this period of exposure had ended, resazurin (150 µM final 
concentration) was added to each well and the plates were shaken for 10 s before another 
3 h incubation period at 37oC to allow viable cells to reduce the resazurin to resorufin. 
Fluoresence intensity for resorufin was detected by a FLUOstar Omega scanning 
microplate spectrofluorometer (BMG LABTECH GmbH, Ortenberg, Germany) using an 
excitation wavelength of 560 nm and an emission wavelength of 590 nm. This assay was 
replicated three separate times and each replication, the fluorescence emission values of 
resorufin in treated cells were normalized to the mean resorufin emission values of the 
untreated control cells (100% metabolically active, viable cells).37 
Synthesis of 3-chloro-1-propanol ester actinocin; a model for actinomycin Y5 
Described in Figure 4.2.1 (a) is the synthesis scheme used to synthesize 3-chloro-
1-propanol ester actinocin. It is very similar to the procedure used to synthesize methyl 
actinocin in Section 2.1.  (1) 3-hydroxy-4-methyl nitrobenzoic acid (0.52g) was dissolved 
in 15 mL of 3-chloro-1-proanol in a 50 mL round bottom flask. 4 mL of thionyl chloride 
was added dropwise with stirring. The mixture was heated to 60oC under a reflux condenser 
and left to react overnight. Saturated sodium bicarbonate and ethyl acetate were added to 
extract the product, 3-hydroxy-4-methyl-1-3’chloropronaol-nitrobenzoic ester. The 
organic layer was separated, dried with sodium sulfate and the excess ethyl acetate was 
removed in vacuo. However, we were unable to completely remove the excess 3-chloro-1-
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propanol due to its organic solubility and viscous nature leading to a high boiling point. 
However, we decided to proceed with the following reaction. 
 (2) To a clean, dry 50 mL double-necked round bottom flask, a few spatulas of 
palladium on activated carbon were added. The flask was then sealed and the air was 
removed and replaced by nitrogen gas. 3-hydroxy-4-methyl-1-3’chloropronaol-
nitrobenzoic ester was dissolved in 20 mL anhydrous methanol and injected into the sealed 
flask. Hydrogen gas was then bubbled into the mixture at room temperature. The reaction 
was left under hydrogen gas for 48 hours. The palladium on activated carbon was removed 
by vacuum filtration through celite. Methanol was removed in vacuo leaving the remaining 
3-chloro-1-propanol and the product 3-hydroxy-4-methyl-1-3’chloropronaol-anthranilic 
ester 
 (3) 10 mL of methanol and 10 mL of 0.067M potassium phosphate solution were 
added to the remaining solution of 3-hydroxy-4-methyl-1-3’chloropronaol-anthranilic 
ester and 3-chloro-1-propanol along with 1.16g of potassium ferricyanide. 1.5 mL of 2M 
sodium hydroxide was added to the mixture to readjust the pH into the 7-8 range.67 This 
produced an insoluble orange solid, likely an iron complex. The solution was covered in 
tin foil and stirred at room temperature under nitrogen balloon overnight. The orange 
insoluble flakes were removed by filtration through celite. A PLC silica gel was run (5:1 
hexanes:ethyl acetate) to reveal five different spots. These spots were scratched out of the 
PLC silica gel and extracted, extracted with ethyl acetate and subjected to LC/MS. It was 
revealed that the yellow product (third spot from the top of the gel) was the product. The 
remainder of the concentrated reaction mixture was separated by silica column (3:1 
hexanes:ethyl acetate). Concentrated orange/yellow fractions were collected and 
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concentrated in vacuo. A small amount of liquid remained in the round bottom flask and 
was discarded, assuming it was contaminant. The remaining red solid was washed via 
vacuum filtration with pentane, dried. Total yield of all three reaction steps was 11.25% 
(68.63 mg). 
Reaction conditions to form β-ring heterocycle in 3-chloro-1-propanol ester actinocin 
To a 50 mL round bottom flask, 4.24 mL of  10 mM 3-chloro-1-propanol ester 
actinocin stock solution (0.0424 mol) was dried and redissolved in 5 mL 
dimethylformamide (DMF). To this, 33 mg of cesium carbonate (1.01E-04 mol) and 5.63 
mg of sodium iodide (3.77E-05 mol) were added. The mixture was stirred at 60oC under a 
reflux condenser overnight.77  
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Figure 4.2.1-Synthesis Scheme for 1-Chloro-3-Proponal Actinocin and Underlying 
Logic 
(a) 
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Synthesis scheme to synthesize 3-chloro-1-propanol ester actinocin. The heterocycle 
formed in our model compound would form a similar shape and contain a β-ring 
heterocycle of the same size as actinomycin Y5.  
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4.3 Results and Discussion 
Activity of Newly Discovered Actinomycin Y compounds 
 The results from this MIC assay to determine antibacterial activity are summarized 
in Table 4.3.1(a). Once again, actinomycin Y6 yielded the most interesting results when 
compared to the activity of actinomycins Y3 and Y4. The muted but measurable activity of 
actinomycin Y6 against the gram positive bacteria tested is a substantial improvement over 
the immeasurable activities of Y3 and Y4 indicating that the β-ring heterocycle does restore 
some of the efficacy lost from the β-ring core rearrangement. This confirmed part of our 
hypothesis in Section 3.3 and Figure 3.3.4; the tighter, more compact shape that is near 
the correct plane for DNA binding of actinomycin Y6 appears to lead to an improvement 
in activity. However, actinomycin Y6 is still several thousand times worse as an antibiotic 
when compared to the activity of actinomycin D, a far cry from the less than 10-fold 
difference observed in antibacterial activity between actinomycin D and actinomycin Y5 
(Tables 1.3 and 4.3.1(c)).35 Actinomycin Y7 also showed considerably poor but measurable 
activity against gram positive bacteria. This is consistent with results observed from testing 
the antibacterial potentcy of actinomycin Z1.36  
Against the cancer cells lines tested (Tables 4.3.1 (b) and (c)), the results were 
consistent with previously observed structure-activity trends. Actinomycin Y6 showed 
extremely poor activity compared to actinomycin D, though overall showed nanomolar 
EC50 against PC3 and A549 cancer cells. Previous cytotoxicity assays done to determine 
the GI50 of actinomycin Y family members Y3, Y4, and Y5 all showed immeasurable or 
µg/mL quantities required to prevent growth in HM02 gastric adenocarcinoma cells, 
HepG2 hepatocellular carcinoma cells, and MCF7 breast adenocarcinoma cells.35 In our 
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hands, we were able to determine a measurable EC50 value for Y3 and Y4, which we found 
to be over 100 times less potent than Y6 and nearly 100,000 times less potent than 
actinomycin D. This drastic change in activity likely means that the cancer cells tested are 
particularly susceptible to actinomycin Y6 or that the combination of β-ring core 
rearrangement and β-ring heterocycle is much more active against cancer cells than having 
either of these structural modifications alone. Again, actinomycin Y7 proved to be just as 
ineffective at instigating cell death as previously reported actinomycins containing a β-ring 
4-hydroxythronine and actinomycins with fewer proline hydroxylations (i.e. actinomycin 
Y9 vs actinomycin Y8) proved to be more active.35-36 
Activity of Newly Discovered Actinomycin Z compounds 
 The minimum inhibitory concentrations (MIC) of the isolated actinomycin Z 
compounds were determined according to the same protocol used to determine those of the 
actinomycin Y compounds outlined in Section 4.2. However, these compounds were only 
tested against the bacterial strains Staphylococcus aureus ATCC 6538 and Escherichia coli 
ATCC 12345. The results are summarized in Tables 4.3.2(a) and (b) and are largely similar 
to what we observed in the actinomycin Y family. Compounds 6 and 8 containing the 4-
chlorothreonine moiety (and likely the previously discovered actinomycins Z5 and Z3, 
respectively) performed similarly to actinomycin D against the cell types tested. However, 
compound 7 (dubbed Z7) likely has both a 4-chlorothreonine moiety but also has an oxime. 
While the location of this particular hydroxyl group is interesting, potentially hinting at 
another actinomycin that could be a result of the phenoxazinone-core reactivity, it does 
seem that having three exposed hydroxyl groups on an actinomycin scaffold reduces the 
bioactivity of the molecule 1000-fold. The activity of compounds 3 and 9 supports this 
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claim. Compounds 1 and 2 both appear to have β-ring heterocycles as a part of their 
structure. However, it is impossible to tell if these compounds are more similar to 
actinomycin Y5 with the actinocin core intact or to actinomycin Y6 with a rearranged core 
from HRMS data alone. Likewise, it is also impossible to discern if any of the multi-
hydroxylated compounds possess a rearranged core with this being the reason for their lack 
of activity, though we believe Vial 3 (dubbed Z8) does when factoring in previously 
discovered actinomycins and unique elution time. 
Characterization of 3-chloro-1-propanol ester actinocin and β-ring heterocycle 
formation 
 
The model compound 3-chloro-1-propanol ester actinocin was successfully 
synthesized and characterized (Figures 4.3.1(a)-(e)). We were, then, able to form a β-ring 
heterocycle in our model 3-chloro-1-propanol ester actinocin (Figure 4.3.2(a)-(h)). A 
sample of the reaction mixture was taken after 17 h and revealed a new peak at ~15.5 min 
(Figure 4.3.2(b)). Of note, the UV profile did change between starting material and 
product, raising a new UV maximum at ~310nm (Figure 4.3.2(d), (g), and (h)). This would 
seem to confirm that the formation of a β-ring heterocycle that attaches to the actinocin 
core at the 2-NH2 position causes the shift in UV absorption. We hypothesize that any non-
UV active group attached to that position is likely to cause this same shift in absorption.  
 The reaction conditions present in Figure 4.3.2(a) were repeated without the 
inclusion of sodium iodide to test if the halide replacement is required to stimulate the 
formation of the β-ring heterocycle. A sample of this reaction mixture was subjected to 
LCMS; while the mass of the cyclized product was observed at the correct elution time, its 
abundance was incredibly small to the point of it being unlikely the formation of the 
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cyclized product would’ve been noticed had we not been looking for it. Reaction conditions 
with and without the presence of sodium iodide will be tested for the β-ring heterocycle 
formation in the 4-chlorothreonine containing actinomycin Z5. We hypothesize that this 
moiety is a better electrophile than the chlorine atom of the 3-chloro-1-propanol ester 
actinocin involved in the cyclization.  
It is also worth noting that the base used in these reactions, cesium carbonate, has 
a pKa of 10.33, which we would consider a mild base. The carbonate ion itself is widely 
available in nature and there are several other naturally found basic compounds that could 
interact with actinomycins after their assembly to cause this rearrangement. The cesium 
counter ion appears to be important to help solubilize the base in DMF as compared to 
sodium and potassium carbonate.78 
 
 
 
 
 
 
 
 
 
 
    
166 
 
Table 4.3.1-Activity of Newly Discovered Actinomycin Y Compounds 
(a) 
 
 
(b) 
 
 
(c) 
 
 
4.3.1(a) displays calculated MIC values for a variety of Gram-positive, Gram-negative, 
and spore forming bacteria; 4.3.1(b) displays calculated IC50 values for PC3 (prostate) 
cancer cells and A549 (lung) cancer cells.37 4.3.1(c) displays the ratio of activity of the 
newly discovered actinomycins Y6-Y9 to the actinomycin D tested during each respective 
MIC or IC50 determinations, as was done for Table 1.3.  
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Table 4.3.2- Activity of Isolated Actinomycin Z Compounds 
 
(a) 
 
 
(b) 
 
 
4.3.2(a) displays calculated EC50 values for for PC3 (prostate) cancer cells and A549 (lung) 
cancer cells; 4.3.2(b) displays the ratio of activity of the isolated  actinomycins Z 
compounds (denoted as samples 1-9) to the actinomycin D tested during each respective 
MIC or IC50 determinations, as was done for Table 1.3. This includes the antibacterial 
activity; activity was only observed against S. aureus for all compounds tested.  
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Figure 4.3.1(a)- Mass spectrum and Total Ion Chromatogram of 3-chloro-1-propanol ester actinocin 
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Figure 4.3.1(b)- 1H NMR of 3-Chloro-1-Propanol Ester Actinocin 
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Figure 4.3.1(c)- gCOSY of 3-Chloro-1-Propanol Ester Actinocin 
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Figure 4.3.1(d)- gHMBC of 3-Chloro-1-Propanol Ester Actinocin 
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Figure 4.3.1(e)- gHSQC superimposed onto gHMBC of 3-Chloro-1-Propanol Ester Actinocin 
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Figure 4.3.2(a)- Reaction done to form β-ring heterocycle in model compound 3-
Chloro-1-Propanol Ester Actinocin 
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This Total Ion Chromatogram highlights a peak at 15.603 min. 
 
Figure 4.3.2(b)- TIC of product mixture from the reaction described in Figure 4.3.2(a) 
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Figure 4.3.2(c)- HRMS spectrum of peak at 15.603 min 
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Figure 4.3.2(d)- UV spectra of peak at 15.603 min  
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This Total Ion Chromatogram highlights a peak at 17.392 min. 
 
Figure 4.3.2(e)- TIC of product mixture from the reaction described in Figure 4.3.2(a) 
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Figure 4.3.2(f)- HRMS spectrum of peak at 17.392 min 
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Figure 4.3.2(g)- UV spectra of peak at 17.392 min  
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 Figure 4.3.2(h)- UV spectra of peak at 15.603 min (black) overlaid with UV spectra of peak at 17.392 min (red)  
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Chapter 5: Results Summary and Future Directions 
5.1 Results Summary 
 This dissertation began with the goals to validate the biological activity of the novel 
actinomycin structure, actinomycin Y5, and to expand upon it’s antibiotic potential. 
However, in the quest to achieve those goals we learned several things about the physical 
properties of the actinomycin aromatic core, the breadth of actinomycin familial diversity 
produced by two strains of Streptomyces species, the biological activity of the newly 
discovered actinomycin compounds, and the conditions under which β-ring heterocycle 
formation can instigated. The results from this quest will be summarized here and their 
implications discussed below.  
 Firstly, the actinomycin core appears reactive enough to perform an SN2 style of 
nucleophilic attack upon the 4-chlorothreonine unit found in actinomycins such as Y1 and 
Z5. Interestingly, it would appear that the 2-NH2 aniline position of the methyl actinocin 
model compound has two acid dissociation constants, though one is much more relevant 
to the formation of the heterocycle found in actinomycin Y5. With an upper bound pKa of 
8.429, methyl actinocin is deprotonated in neutral water approximately once per fifty 
molecules. This result answers a question related to the motivation to develop this model: 
if the 2-NH2 position of the actinomycin core was reactive enough to form the β-ring 
heterocycle found in actinomycin Y5 via an SN2 mechanism, why did the compound not 
occupy a larger share of the actinomycins produced in the Y-family? This level of reactivity 
would explain this paradox; such a nucelophic attack would be a rather uncommon 
occurrence. Furthermore, the noticeable fluctuation in UV absorption between 300-350 nm 
of the methyl actinocin at pH’s above the calculated upper bound pKa proved to validate 
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an observed oddity in some of the newly isolated actinomycins (Figure 2.3.1 and Figure 
2.3.2). We attributed this change in UV absorption to a change in state at the 2-NH2 position 
of methyl actinocin.  
 Once it was determined that the β-ring heterocycle of actinomycin Y5 could be 
formed by nucleophilic attack, it was important to rule out any enzymatic alternatives. 
Through a comparative analysis of the actinomycin G, Y, and Z gene clusters, there appears 
to be no obvious inclusion or exclusion of genomic data that would be responsible for the 
formation of a new actinomycin structural motif. The actinomycin G, Y and Z clusters were 
chosen for this comparative analysis because they were the three actinomycin families that 
utilized a 4-chlorothreonine component in the β-ring depsipeptide. Because of this genome 
similarity between the actinomycin G, Y, and Z clusters, we hypothesized that there were 
undiscovered actinomycin Z family members that would contain a β-ring heterocycle. 
Based on HRMS and UV absorption maxima between 300-320 nm, we believe that we 
have isolated not only actinomycin that contain our motif of interest but also actinomycins 
that contain an oxime at the 2-NH2 position (Figures 3.4.5(a)-(k) and Figures 3.4.11(a)-
(g)). Such an actinomycin structure would not be without precedent: Wang et al. discovered 
the neoactinomycins, which contain a nitrogen-oxygen bond at that position as a result of 
an intracellular reaction with pyruvate and Brockmann et al. was able to synthesize an 
actinomycin analogue containing a similar motif.2, 23 Surprisingly, in our search for 
actinomycin Y5 from the producing Streptomyces GÖ-GS12, we found a second 
actinomycin Y family member containing a β-ring heterocycle: actinomycin Y6, which, 
curiously, contains both the structural motif of interest but also the rearranged β-ring core. 
This discovery challenged the perceived mechanism of formation of the β-ring heterocycle 
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as there is no chlorine electrophile for the 2-NH2 group to attack in an SN2 manner after 
the β-ring core undergoes its rearrangement via two-fold acyl shift.72 
 These newly isolated actinomycins were tested for their biological activity against 
several types of bacteria and cancers. Those activities were compared to that of 
actinomycin D against the same cell types to form a ratio of biological activity that could 
be compared to other actinomycins who’s biological activity was tested at different times 
against different cell lines (Tables 1.3, 4.3.1 and 4.3.2). This comparison led us to the 
conclusion that the β-ring heterocycle did something unique to the activity of those 
actinomycins containing this motif. Using a Gaussian optimization model, we predicted 
that the tighter, more confined shape of the β-ring heterocycle-containing compounds was 
responsible for this activity.74 This gave us hope that the antibacterial potential for 
actinomycin Y5 was not a result of experimental design but could be a unique property of 
the molecule. However, in our hands, actinomycin Y6 showed mild biological activity 
against both gram positive bacteria and the cancers tested instead of the antibacterial 
selectivity observed in the initial biological screening of actinomycin Y5.37 Furthermore, 
the biological activities observed in the actinomycin Z compounds were similar to those 
observed in the actinomycin Y family and consistent with all of the structure-activity 
relationship data compiled in Section 1.3 with one notable exception: compounds that we 
believe contain β-ring heterocycles did not show improved antibacterial activity compared 
to their cytotoxicity. These studies are being repeated to confirm this activity.  
 The discrepancy in activity between actinomycins Y5 and Y6 as well as the 
actinomycin Z compounds predicted to posses a β-ring heterocycle or have an oxime at the 
2-NH2 position posed a problem: if we were interested in developing these compounds as 
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potential therapeutics, what are the conditions under which we can make one of these 
structures but not the others? Can the β-ring heterocycle be formed under mild chemical 
conditions—like those found within a bacterial cell—at all? The model compound we 
synthesized—3-chloro-1-propanol ester actinocin—was found to cyclize in the presence 
of cesium carbonate, sodium iodide, and mild heat, which would likely indicate that this 
SN2 cyclization could occur naturally, albeit more slowly. We then applied those conditions 
to the actinomycin Y1 and Z5 compounds we isolated; the results of those experiments are 
not yet available. 
 All of this data taken together—the pKa of the actinomycin core, the gene cluster 
similarity between families of actinomycin, the novel compounds discovered, and the 
cyclization conditions observed in the model 3-chloro-1-propanol ester actinocin—leads 
us to the conclusion that the actinomycin Y and Z gene clusters produce a single product 
and the familial diversity observed in culture is due to the reactivity of the actinomycin 
core. This conclusion is visualized in Figure 5.1.1.  
 Much of the rationale for this conclusion came when analyzing the HRMS and UV 
absorption data for the isolated actinomycin Z compounds (Figures 3.3.5(a)-3.3.13(m)). 
As Section 3.3 articulates, the compounds were isolated as pure peaks from the semi-
preparative HPLC; these compounds were stored in a mixture of acetonitrile and water 
until they were lyophilized and then characterized. During their final characterization, these 
products would appear to have broken down into several products no matter how isolated 
and pure the peak was at the time of its collection. Furthermore, this breakdown often 
occurred in predictable ways and almost always included an isolate with the mass and UV 
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signature indicative of a β-ring heterocycle containing compound, setting up compounds 
like actinomycin Y5 as an unstable intermediate in this degradation pathway.  
 Another piece of evidence supporting this conclusion is the formation of 
actinomycin Y6. As alluded to in Section 3.3, actinomycin Y6 is likely formed after the 
Michael-like attack on the 4-position of the α,β-unsaturated amide, which was made after 
the elimination of the newly exposed hydroxyl group generated after the rearrangement of 
the β-ring core. The difference in structure between 4-chlorothreonine containing 
actinomycins and actinomycins with a rearranged core—both of which form a β-ring 
heterocycle—is pronounced as shown in Figure 3.3.3, and Figure 3.3.4 reducing the 
likelihood a single enzyme could perform both of these reactions. The difference in 
electrophile in each of these cases is also vastly different. Therefore, the driving force 
behind both of these β-ring heterocycle formations is the nucleophilicity of the 2-NH2 
position within the actinomycin core and not the electrophilicity of the group being 
attacked.  
 The final piece of evidence presented here to support this conclusion is that we have 
observed that these heterocyclic products are not a large portion of the metabolites 
collected from the production of this gene cluster, it is reasonable to assume that there is 
no scripted process for their manufacture. Furthermore, these heterocyclic products are not 
as active as the halogenated family members, indicating compounds like actinomycin Y5 
and Y6 would do a worse job at protecting the bacterial producer than a compound like 
actinomycin Y1. Therefore, there would be little incentive for the producing strain to make 
the heterocyclic actinomycins intentionally. There also appears to be no obvious gene 
candidate to make an enzyme that could perform this chemistry
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Figure 5.1.1- Proposed Reactive Pathway Leading to Actinomycin Familial Diversity Within Actinomycin G, Y and Z 
Families 
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5.2 Future Directions 
 The goal at the inception of this research was to confirm the biological activity of 
actinomycin Y5 and to determine if a novel mechanism of action/therapeutic target was 
responsible for its unique activity. However, due to our inability to isolate pure actinomycin 
Y5, we were forced to attempt to create our own and to analyze the possible sources of our 
shortcomings. The areas of analysis we chose to pursue were the physical properties of the 
actinomycin core (Chapter 2), the gene clusters of the actinomycin Y-family producer and 
the closely related actinomycin Z-family producer as well as the secondary metabolites 
produced by each (Chapter 3), and the conditions under which the formation of the β-ring 
heterocycle could occur (Chapter 4). Each of these analyses attempted to answer a logical 
series of questions: is it possible for the actinomycin core to preform an SN2 attack on the 
4-chlorothreonine residue, is there an enzymatic explanation for the formation of this 
structural motif, and can actinomycin Y5 be made with some light medicinal chemistry 
from what is believed to be the primary product of each of the actinomycin Y and 
actinomycin Z gene clusters?  
 Outlined in Section 5.1 are what we believe the answers to these questions to be 
but in our search for these answers, new areas of research have emerged. For example, the 
discovery that the 2-NH2 position on the actinomycin core is reactive allows the possibility 
to create new actinomycin derivatives. Though many derivatives were made between the 
years 1959-72, none of them were made with a purpose beyond probing the structure-
activity relationship of the various components of the actinomycin molecule.22-23, 27-29, 32 
With advancements in solid-phase synthesis increasing the yields of peptide syntheses that 
require multiple steps and with the total synthesis of actinomycin D already known, there 
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is a tremendous opportunity to attach chemical handles or other reactive groups to this site 
in a totally synthetic or semi-synthetic manner.79-81 One opportunity to utilize this handle 
would be to immobilize further the DNA-RNA polymerase complex that actinomycin halts 
as its mechanism of action; this immobilization could aid in obtaining a crystal structure 
of how the three entities interact, something that has yet to be obtained and one of the few 
remaining mysteries of how actinomycin interacts with DNA.14, 82 
 Another area of study that this research could be applied to is the full and accurate 
characterization of the actinomycin Y, Z, and G gene clusters. Though most of the 
actinomycin gene cluster has been characterized, there are several enzymes of interest 
whose function is not understood. For example, one of the most famous mysteries 
concerning the biosynthesis of actinomycin has been the inability to identify the gene 
responsible for the production of the enzyme that unifies the α- and β-rings of the molecule. 
It has been previously reported that the actinomycin chromophore can be synthesized by a 
phenoxazinone synthase; however no gene within the cluster exhibits enough sequence 
similarity to this class of enzyme to be classified as such.44-45, 47, 83-84 Furthermore, several 
of the tailoring enzymes found in the actinomycin G, Y and Z clusters—known as acmG6-
9, acmY14-17, and acmZ14-17 in their respective gene clusters—have not had their 
putative functions identified, though some preliminary work has been reported on this 
group. For instance, acmG9 and its acmY17 and Z17 homologues have all been 
characterized as non-heme α-ketogluterate dependent halogenases and acmG8 and its 
acmY16 and Z16 homologues cytochrome P450 enzymes; these assignments were 
confirmed to be responsible for the chlorination and hydroxylation, respectively, of the β-
ring threonine via knockout and complementation experiments.47 However, in those same 
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experiments, the knockout of either one of these genes abolished the supposed product of 
the other. There could be several explanations for this finding. The class of halogenase of 
which acmG9, acmY17, and acmZ17 belong to has been show to both halogenate and 
hydroxylate under certain conditions.85 It is possible this enzyme’s promiscuity is 
responsible for the generation of both modified threonine units and is enabled by acmG8 
and homologues. It is possible these enzymes form and complex and are inactive without 
one another or are not recruited to the NRPS by some X-domain mechanism without the 
combination of the two; no in vitro assays have been done to confirm the activity of these 
enzymes.86 In Section 5.1, we propose an alternative theory to how familial diversity 
among these actinomycin families is achieved that coincides with all previously observed 
data. If we are correct, then it is likely at least one of these enzymes is performing a function 
that was not previously predicted. Only further testing will illuminate this biosynthetic 
conundrum. Additionally, study of acmG6 and 7 and their Y- and Z family homologues Y 
and Z14-15 have hardly been studied at all. An acmG7 knockout was shown to abolish 
production of actinomycin but a homologue is not present in all actinomycin gene 
clusters.45, 47 It was believed to have been involved in the oxidations of the actinomycin 
proline residues, although that seems unlikely to halt all actinomycin production should it 
be absent given the trivial nature of the proline residues. It carries with it the vague 
annotation of being a member of the SDR_c superfamily of enzymes, which have been 
show to perform various types of redox chemistry.87-88 No knockout was made for acmg6 
and homologues and it is most similar to a bifunctional phosphoglucose/phosphomanose 
isomerase. Given the lack of sugar molecules attached to the final compound, this enzyme 
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is likely performing an unpredicted function during the biosynthesis of these compounds. 
There is plenty to learn about these tailoring enzymes.  
 Additionally, another aspect of actinomycin scaffold formation that requires 
investigation is the reported structure of actinomycin G5; this compound is reported to 
contain a β-ring heterocycle similar to actinomycin Y5 but with an oxygen serving as the 
heteroatom instead of nitrogen.36 Currently, the only piece of evidence to support the claim 
of a different heteroatom between actinomycin G5 and actinomycin Y5 is the difference in 
carbon NMR at β-ring position HThr-4 (δC 68.48 for G5 and 45.3 for Y5).35-36 This would 
indicate the carbon at this position in actinomycin G5 is adjacent to a more electronegative 
atom causing greater electronic deshielding, which would imply the presence of an oxygen 
atom as opposed to a nitrogen. A possible mechanism for this type of spontaneous 
heterocycle formation is shown in Figure 5.2.1. However, this mechanism relies on the 
deprotonation of the hydroxyl group at β-ring position HThr-4 by the 2-NH2 aniline group, 
a phenomenon that seems extremely unlikely given the difference in basicity between the 
2-NH2 aniline and the hydroxyl group (pKa 8.429 vs ~16) and in the time spent working 
with the actinomycin Y actinomycin Z families, we have not yet come across a congener 
containing this structural motif, which we would expect given the closeness of these 
families to actinomycin G both genetically and structurally. We would like confirm the 
uniqueness in structure of actinomycin G5 ourselves.  
 The actinomycins have also recently been used in a salamander tail regeneration 
assay (Figure 5.2.2) similarly to previously published assay results.89 The assay showed 
that actinomycins D, Y1, and Z1 inhibited regenerative growth of cut salamander tails at a 
10 µM concentration but that actinomycin Y6 did not. This provides some anecdotal 
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evidence that the doubly hydroxylated actinomycin Z1 does make it past the cellular 
membrane and that actinomycin Y6 does not bind DNA. Since we hypothesized that overly 
hydroxylated actinomycins might have decreased activity due to a lack of availability at 
the site of action and that the formation of the β-ring heterocycle would rescue some of the 
activity lost by the rearrangement of the β-ring core in actinomycin Y6, it is worth pursuing 
experiments that challenge our initial hypothesis.   
 One final aspect of this work that requires further exploration—and might be the 
most relevant topic to the development of a new medication—is the stabilization of the β-
ring heterocycle and the determination of how the constricted shape interacts with DNA. 
There have been numerous studies examining the structure-activity relationships between 
various additions to the actinomycin scaffold. It has become clear through the work shown 
here in Section 4.3 and the works collected in Section 1.3 that additional oxidations to the 
proline and threonine residues greatly reduce the biological activity of the compounds; a 
rearrangement to the β-ring core appears to have a similar effect.2, 34-35, 37-38 This reduced 
activity could be caused by inefficient binding to DNA, an inability for the more polar 
compounds to traverse the cellular membrane, the addition of chemical handles that could 
be acted upon by possible resistance mechanisms, or some combination of all three.90 
However, the addition of a chlorine group to the β-threonine does not appear to diminish 
the compound’s efficacy relative to actinomycin D. Interestingly, the activity of the 
rearranged actinomycins can be rescued by forming a β-ring heterocycle, which—
according to a Gaussian optimization program—readjusts the binding plane of the 
rearranged actinomycins to be similar to that of actinomycin D.37, 74  
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 The secondary amine linkage that forms the β-ring heterocycle appears to be acid 
labile, which would make it unlikely to survive the various conditions a drug is exposed to 
in vivo.37 Fortunately, it would appear that the three dimensional shape of the actinomycin 
molecule to be more important for activity than the heteroatoms away from the actinocin 
core. This gives us the freedom to install other heteroatoms or groups in place of the acid-
labile amine to maintain the structure the β-ring heterocycle creates. For example, 
phosphate can be inserted in place of nitrogen to utilize its ability to form five stable bonds, 
much in the same way that sarin gas binds to acetocholinesterase (Figure 5.2.3).91-92 
Another alternative would be to remove the heteroatom from the formation of this 
additional β-ring by utilizing olefin metathesis (Figure 5.2.4).93 These pathways could be 
used to expand on contract the size the additional ring as well. This would provide 
numerous insights into the behaviors of this new, constricted actinomycin, while also 
making our potential drug more stable.  
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Figure 5.2.1- Possible Mechanism to Explain the Structure of Actinomycin G5  
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Figure 5.2.2- Results of Salamander Tail Regeneration Assay  
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Figure 5.2.3- Sarin-like Mechanism and Incorporation in Actinomycin Scaffold 
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Figure 5.2.4-Installation of Non-Reactive Linkage Actinomycin Core and β-Ring 
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